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ABSTRACT 
 
Chemokines are key mediators of inflammation and are involved in both 
extrinsic and intrinsic pathway of cancer. Their main function is to induce leukocyte 
migration through the binding of specific seven transmembrane receptors. Beside 
canonical chemokine receptors, a smaller family of atypical chemokine receptors was 
described. ACKR2 binds with high affinity a broad panel of CC inflammatory 
chemokines mediating their internalization and intracellular degradation. Due to its 
chemokine scavenging activity, ACKR2 plays a protective role in chronic 
inflammation and in the extrinsic pathway of cancer.  
The objective of my thesis was to investigate the role of ACKR2 in the intrinsic 
pathway of cancer using the NeuT (HER2) murine model of oncogene-driven breast 
cancer crossed with Ackr2-/- mice. In this model, we found that ACKR2 plays a dual 
and opposite role. It slows the primary tumor development while it promotes lung 
metastasis. We found the same phenotype about metastasis using the orthotopically 
transplanted 4T1 mammary carcinoma and melanoma B16F10 cell lines. We 
demonstrated that ACKR2 expression in the hematopoietic compartment acts as a 
negative regulator of the mobilization of neutrophils with anti-metastatic function. 
In the last part of my thesis we also investigated the phenotype of circulating 
and tumor associated neutrophils (TANs) in glioma patients, a tumor context 
characterized by blood neutrophilia and a general immunosuppressive state. We found 
a higher grade of neutrophilia and an increased rate of immature neutrophils in 
glioblastoma patients compare to grade III glioma patients. Finally, we found that the 
relative abundance of circulating neutrophils on total leukocytes positively correlates 
with relative abundance of TANs. 
Collectively taken, these results indicate that neutrophils are a heterogeneous 
population with both pro and anti-tumoral functions. Targeting of neutrophils in cancer 
context represent a potential therapeutic approach that limit their pro-tumoral role 
unleashing the anti-tumoral and anti-metastatic potential.  
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1 INTRODUCTION 
 
1.1 Cancer-related inflammation 
Since from the first observations made by Rudolf Virchow in 1863 in which he noticed 
leukocytes inside neoplastic tissue, it was suggest that cancer and inflammation are 
linked to each other [1]. From that moment, several evidence sustained a direct link 
between cancer and inflammation. Today, it is established that chronic inflammation 
supports carcinogenesis and conversely, cancer cells create an inflammatory 
microenvironment that sustain tumor growth [2, 3].  
 
 Two pathways link inflammation to cancer 
The inflammatory process is described as a necessary but not sufficient cause of 
cancer. Several epidemiological studies indicate an association between chronic 
inflammation and organ-related cancer type indicating that patients with chronic 
inflammation are more susceptible to develop various cancer type [1, 4]. Nevertheless 
during all stages of cancer progression (from carcinogenesis to metastasis) it is 
registered an high amount of inflammatory mediators produced by cancer or stromal 
cells that lead to recruitment of pro-tumoral leukocytes that sustain tumor growth and 
spread [5]. The link between cancer and inflammation can be recapitulated in two 
pathways of cancer development: the extrinsic pathway and the intrinsic pathway. In 
the extrinsic pathway, a pre-existing chronic inflammation and the concomitant 
exposure to mutagen agents (for example smoke, ionic radiations, aromatic 
compounds) increase the risk to develop cancer. This observation is sustained by 
epidemiologic studies that indicate patients with chronic inflammation more 
susceptible to develop cancer [2] and experimental preclinical models in which mice 
exposed to chronic inflammatory and consequently mutagen agents are prone to 
develop cancer (Fig. 1.1) [6]. On the other hand, in the intrinsic pathway, after 
transformation cancer cells are able to produce or to induce the production of 
mediators of the inflammation such as cytokines, chemokines and prostaglandins. This 
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latter characteristic, belonging also to the extrinsic pathway, create an inflammatory 
microenvironment that enhance in a direct way tumor growth and metastasis spread 
and in an indirect way recruitment of corrupted leukocytes that sustain tumor growth 
and metastasis dissemination (Fig. 1.1) [2]. Finally, all these evidence indicates 
inflammation as a fundamental hallmark of tumor initiation, progression and spreading 
[3, 7]. 
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Figure 1.1: Two pathways link inflammation and cancer. In the extrinsic pathway, 
chronic inflammation increased cancer susceptibility after mutagen exposure. In the 
intrinsic pathway, mutated oncogene or tumor suppressor gene causes cell 
transformation. Both pathway converge in the production by cancer or stromal cells of 
mediators of inflammations [2]. 
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 Myeloid cells in cancer-related inflammation  
As discussed above, mediators of inflammation are present in both pathway of cancer-
related inflammation. One of the features exerted by mediators of inflammation is the 
recruitment of leukocytes that infiltrate the tumoral mass. Leukocytes are recruited 
from the blood stream to tumoral side by cytokine and chemokine produced by cancer 
cell and stromal cells. Both myeloid and lymphoid cells are involved in this process 
and play at the same time pro-tumoral and anti-tumoral functions depending on the 
concentration of polarizing cytokine. In detail, myeloid infiltrating cells include tumor 
associated macrophages (TAMs), tumor associated neutrophils (TANs) and monocyte-
derived dendritic cells (mo-DC) [8]. Two categories belong to TAMs: tissue resident 
macrophages that are present in the neoplastic tissue before cell transformation and 
circulating monocytes that are recruited in the tissue and then differentiate to 
macrophages. TAMs differentiate into anti-tumoral phenotype (M1) and pro-tumoral 
phenotype (M2) depending on microenvironment cytokines. Macrophages are defined 
plastic cells based on their capacity to change their phenotype from M1 to M2 or vice 
versa [9]. The same paradigm was recently attributed to TANs. Neutrophils, as 
discussed in the related paragraph of this thesis, are described to polarize, as 
macrophage, in the tumor microenvironment to anti-tumoral (N1) and pro-tumoral 
(N2) phenotype. Otherwise, the concept of neutrophil plasticity is not completed 
elucidated at the moment [10]. For dendritic cell the polarization paradigm is not 
recognized, while it is well described their role as antigen presenting cells (APC) of 
danger associated molecule pattern (DAMP) released during cell death that enhance 
the adaptive immune anti-tumoral response [11]. 
 
 Targeting cancer-related inflammation 
Being inflammation a fundamental hallmark of cancer, its target represents an 
important therapeutic strategy [12]. Today, two main therapeutic strategies emerge as 
target of cancer-related inflammation.  
The first strategy to target CRI is inhibition of the production of inflammatory 
mediators in the tumor microenvironment [13]. For example, genetic ablation of COX-
1, COX-2 and prostaglandin E2 reduce inflammation and primary tumor growth 
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enhancing anti tumoral leucocytes activity [14]. The second attempt is to directly 
inhibit leukocyte infiltration of the tumors. The best example of this strategy is the use 
of antibodies blocking the chemokine CCL2, that is the main macrophage 
chemoattractant, that inhibits lung metastasis in breast cancer model [15].  
Chemokines are mediators of inflammation involved in cancer and leukocytes biology, 
angiogenesis and other important process in cancer biology. In the following paragraph 
the role of chemokine as mediator of inflammation in cancer will be elucidated. 
 
1.2 Chemokines 
Chemokines are a large family of chemotactic cytokines including more than 50 
related molecules. The name “chemo-kines” derives from their ability to induce 
chemotaxis in responsive cells, that express dedicated chemokine receptors. Common 
features of chemokines, despite a low amino acid sequence homology, are four well-
conserved cysteine residues, which form two disulphide bonds between the first and 
the third cysteine and between the second and the fourth. These bindings give to 
chemokines a conserved tertiary structure, with a disordered amino-terminus, three-
stranded antiparallel β-sheets and a carboxy-terminal α-helix [16].  
The chemokine system is described as redundant and promiscuous because it is 
composed by more that 50 ligands recognized by only 22 receptors (Fig. 1.2) [17, 18]. 
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Figure 1.2: The chemokine system. Chemokines, their related receptors and 
expression on leukocytes [17] 
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 Chemokine classification 
Depending on the position of cysteine residues in their N-terminus, chemokines are 
divided in four subfamilies: CC, CXC, C and CX3C [19, 20]. CC chemokines are the 
most represented group of chemokines and have the first two of the four cysteine 
residues in adjacent position while CXC chemokines have one amino acids between 
the first two cysteines (Fig. 1.3). CXC chemokines can be further classified in ERL- 
and ERL+ chemokines, depending on the presence of the ELR (Glu-Leu-Arg) motif. 
On the other hand, CX3C chemokines have three amino acids separating the two 
cysteines and C chemokines have only two cysteines [18]. 
Moreover, chemokines are classified in homeostatic and inflammatory depending on 
the regulation of their expression. Homeostatic chemokines such as CCL19, CCL20 
and CCL21 are constitutively produced and regulate leukocytes migration in healthy 
condition. On the other hand, inflammatory chemokines such as CC chemokines (e.g. 
CCL2, CCL3, CCL5) and ELR+ chemokines (e.g. CXCL8) are expressed during 
pathological condition and are secondary inflammatory mediators induced by pro-
inflammatory mediators (e.g. IL-1 and TNF- α) [21]. 
 
 
 
Figure 1.3: Classification of chemokines. Chemokine classification depends on the 
presence and the number of amino acids between the two first cysteines that form the 
two disulphure bounds with other cysteines in the sequence. Chemokine are classified 
in CC, CXC, C, CX3C [22].  
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 Chemokine receptors 
Chemokines are soluble mediators acting on specific target cells that express related 
chemokine receptors. Chemokine receptors are classified according to the family of 
chemokines that bind in CXCR, CCR, CX3CR, or XCR1. Chemokine receptors belong 
to the superfamily of 7-transmembrane receptors [16] coupled to hetero-trimeric GTP-
binding proteins (G-protein) of the Gi type, sensitive to Bordetella pertussis toxin. 
Chemokine receptors have a highly-conserved structure constituted by a single peptide 
chain with three intracellular and extracellular loops, an external N-terminus domain 
essential for the specificity of ligand binding, and an intracellular carboxy-terminus 
tail. This latter domain, together with other motifs, such as the DRYLAIV (Asp–Arg–
Tyr–Leu–Ala–Ile–Val) motive between the third transmembrane domain and the 
second intracellular loop, has a role in receptor signaling (Fig. 1.4). After chemokine 
binding, conformational changes occur and trigger intracellular signaling pathways 
promoting cell migration or activation [23]. 
 
 
 
Fig 1.4: Structure of chemokine receptor. CCR5 as example of chemokine receptor 
structure [24] 
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 Chemokines in cancer 
Beyond the role of regulator of leukocytes mobilization, chemokines have a key role 
in many other functions: they regulate angiogenesis, fibrosis, cell proliferation and also 
cancer cell growth and dissemination. Chemokines are involved in both pathways that 
link inflammation to cancer. In the extrinsic pathway, chemokines are key mediators 
of chronic inflammation that increases the risk to develop cancer. In the intrinsic 
pathway, in which cancer raises from genetic events, chemokines expression is 
regulated by oncogenic pathways and transcription factors altered in cancer cells [25]. 
As discussed above, chemokines can act both on cancer and on stromal cells. 
Chemokines secreted at tumor site can recruit both immature cells and mature cells. 
Chemokines such as CCL2 and CXCL8 attract at tumor site monocytes and neutrophils 
that then differentiate to tumor associated macrophages (TAMs) and tumor associated 
neutrophils (TANs). TAMs and TANs have both pro-tumoral and anti-tumoral role 
depending on their polarization [8, 10].  Moreover, CCR4 ligands such as CCL17 and 
CCL22 have a role in the recruitment of Treg and Th2 lymphocytes that create an 
immunosuppressive microenvironment contributing to tumor growth [26]. On the 
other hand, ligand of CXCR3, CX3CR1 and CXCR6 increased mobilization of NK 
cells and T lymphocytes, cells able to kill cancer cells through direct cytotoxic effect 
[25, 27]. Chemokines have a key role also in the angiogenetic process enhancing or 
inhibiting de novo vessel formation and vessel spread. Pro-angiogenetic effects are 
exerted by ELR+ CXC chemokines and CXCL12, ligand of CXCR2 and CXCR4, that 
promote angiogenesis and inhibit apoptosis of endothelial cells [27]. On the other 
hand, ELR- chemokines such as CXCL9, CXCL10, and CXCL11 bind CXCR3 
expressing cells (Th1 lymphocytes and NK cells) and inhibit angiogenesis through the 
expression of type 1 cytokine [27-30]. A fundamental role of chemokines in the cancer 
context is the primary cancer spreading to secondary organs (metastasis). CXCR4 is 
the main receptor involved in this process. CXCR4 expression on cancer cells is up-
regulated in many cancer type and CXCR4 positive cells have an increased migration 
to organs that express high level of the ligand CXCL12 such as lung, lymph node, 
bones and liver. Pharmacological block of the CXCL12/CXCR4 axis impairs 
metastatic seeding in different preclinical tumor models [31, 32]. Moreover, some 
tumors can express CCR7 and use it to migrate into lymph nodes because lymphatic 
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vessels express high amount of the ligand CCL21 [33]. Finally, chemokines have also 
a direct role in cell survival activating cancer cells via the PI3K-AKT-NF-kB and the 
MEK1/2 and Erk1/2 axis [34, 35]. 
 
1.3 Atypical chemokine receptors 
Beyond canonical chemokine receptors, a new subfamily of chemokine receptors 
defined “atypical” has been recently identified and nomenclated [36]. Atypical 
chemokine receptors (ACKRs) have structural features similar to canonical chemokine 
receptors but have a modified DRYLAIV motif and after ligand binding, the receptors 
do not induce any G protein mediated signaling and cell mobilization. ACKRs bind 
with high affinity CC and CXC chemokines and their functional role is the regulation 
of chemokine availability. Their role is exerted scavenging, transporting or directly 
controlling signaling of other chemokine receptors [37]. Four members composed the 
ACKRs family: ACKR1 (previously nomenclated DARC), ACKR2 (D6), ACKR3 
(CXCR7) and ACKR4 (CCX-CKR) (Fig. 1.5) [36, 38]. Our research group has 
focused the attention on ACKR2, a negative regulator of CC chemokines [38, 39].  
 
 
Figure 1.5: The atypical receptors family. Current and traditional nomenclature of 
atypical chemokine receptors, their ligand and canonical receptors which ACKRs act 
as agonist [37]. 
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 ACKR2/D6 
ACKR2, previously called D6 or CCBP2, is a seven-transmembrane receptor that 
belongs to the atypical chemokine receptor family. ACKR2 binds a broad group of 
inflammatory CC chemokines (ligands of CCR1, CCR2, CCR3, CCR4 and CCR5), 
and leads to their internalization and degradation [39]. ACKR2 structure is different 
from canonical chemokine receptors for a modified DRYLAIV to a DKYLEIV motive 
that not allow binding with G-coupled protein [40]. For this reason, it was supposed 
that ACKR2 was a “silent” receptor not able to trigger any signaling pathway [41-43]. 
In basal conditions, ACKR2 is stored in endosomal vesicles and recycled continuously 
to the membrane [44, 45]. After ligand engagement, ACKR2 internalizes and targets 
chemokines to lysosomal degradation. At the same time, it activates β-arrestin-
dependent signaling, which increases receptor recycling to plasma membrane 
localization to adapt its function in the control of chemokine extracellular 
concentrations [46, 47]. ACKR2 is described to be highly expressed by the 
syncytiotrophoblast layer in placenta, by lymphatic endothelial cells, and by some 
leukocyte populations, including innate-like B cells and alveolar macrophages [48-
50]. ACKR2 role in physiology and pathology was demonstrated using gene-targeted 
mice in which ACKR2 expression is deleted. 
 
 ACKR2 role in physiology  
ACKR2 has a role both in physiologic and pathologic conditions. In homeostasis, 
ACKR2 expressed by efferent lymphatic vessel regulates chemokine levels and 
prevents excessive leukocytes accumulation in the lymphatic system [51, 52]. It 
regulates lymphatic vessel density formation in ear, diaphragm and popliteal lymph 
nodes inhibiting the recruitment of CCR2 positive pro-lymphangiogenic macrophages 
[53]. The ACKR2 scavenger activity of CC inflammatory chemokines is also involved 
in the increased efficacy of the presentation of CCR7 ligand and promotion of DC 
migration [54]. Moreover, ACKR2 controls also the morphogenesis and the branching 
of mammary gland during development [55] and the traffic of inflammatory 
monocytes (CD11b+/Ly6Chigh) with immunosuppressive phenotype inhibiting 
egression from bone marrow [56]. 
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 ACKR2 role in inflammation and autoimmunity 
ACKR2 emerges as negative regulator of the inflammation through its capacity to 
degrade CC inflammatory chemokines. In skin inflammation, ACKR2 exerts a 
protective role after phorbol ester skin painting and following injection of complete 
Freund’s adjuvant (CFA) with a concomitant decrease of the inflammatory response 
[48, 57, 58]. Similar results were found in antimicrobial response to Mycobacterium 
tuberculosis. Ackr2-/- mice display reduced survival rate, increased number of 
leukocytes, increased production of pro-inflammatory cytokines such as TNF-a, IL-
1b, INF-g and chemokines such as CCL2, CCL3, CCL4 and CCL5 [59]. Being the 
syncytiotrophoblast one of the major site of expression of ACKR2, in a LPS-dependent 
fetal loss model, Ackr2-/- mice have an increased abort rate with concomitant increased 
levels of CC chemokine and leukocytes [60]. Contrasting results were published about 
gut inflammation. While Vetrano and colleagues found in Ackr2-/- mice an increased 
inflammation after administration of dextran sulfate sodium (DSS) [61], Bordon and 
colleagues found that Ackr2-/- mice are protected after DSS administration and this 
correlates with increased production of IL-17A by T cells [62]. Further experiments 
are needed to elucidate the role of ACKR2 in this context, taking in consideration 
animal house sanitary status and the intestinal flora. 
Moreover, in a graft versus host disease (GVHD) Ackr2-/- mice have increased number 
of inflammatory monocytes with immunosuppressive activity and they are protected 
from disease development [56]. In human arthropathies, ACKR2 is upregulated in 
synovial tissue as a marker of inflammation [63]. Finally, ACKR2 was described to 
have a role in autoimmune diseases because it was found  upregulated in psoriatic skin 
[64] and Ackr2-/- mice shown a faster disease progression in a psoriasis-induced model 
with increased cell autonomous neutrophil infiltration [65]. On the other hand, Ackr2-
/- mice are protected in the development of autoimmune diabetes [66] and experimental 
autoimmune encephalomyelitis [67], but opposite results in this model are described 
by Hansell and colleagues in which they do not recapitulate phenotype found in the 
first study by the other group [68]. 
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 ACKR2 role in cancer 
ACKR2 plays also a role in cancer through its ability to scavenge chemokines [49, 57, 
62] [38]. ACKR2 role was elucidated using gene-targeted mice in different preclinical 
models. Firstly, ACKR2 was described to have a role in TPA/DMBA skin 
carcinogenesis in which ACKR2-deficient mice developed earlier and increased skin 
tumors [69]. Also in AOM/DSS model, Ackr2-/- mice increased colon cancer 
susceptibility confirming a protective role of ACKR2 in different organs [61]. On the 
other hand, ACKR2 did not affect the development of the DEN-induced hepatocellular 
carcinoma model, even if an increased macrophage infiltration was detected in gene-
targeted mice [70]. Referring to colon cancer, ACKR2 expression in human colon 
adenocarcinoma samples is decreased compared with healthy tissues and correlates 
with an increased lymphatic vessel density and an increased production of CCL22 
[71]. ACKR2 is described to be highly expressed in lymphatic endothelium [39] and 
it is implied in different vascular tumor including Kaposi’s sarcoma spindle cells [54]. 
In this context, ACKR2 expressed by cancer cells have a protective role in tumor 
growth inhibiting inflammatory chemokines such as CCL2, CCL5, and CCL3 with a 
concomitant reduced macrophage infiltration and angiogenesis. 
Immunohistochemistry data reveal that in Kaposi’s sarcoma patients ACKR2 is down-
regulated through the oncogenic pathway KRas/BRaf/MEK/MAPK [72]. ACKR2 has 
a protective role also in breast cancer but the expression in healthy epithelial cells was 
not elucidated [73]. In human breast cancer samples ACKR2 expression is inversely 
correlated to lymph node metastasis and the clinical stage. ACKR2 over-expression in 
a human breast cancer cell line regulates inflammatory chemokines levels and tumor 
aggressiveness in vivo [74]. These data were confirmed by different groups: ACKR2 
was found down-regulated during breast cancer progression, and concomitant down-
regulation of ACKR1 and ACKR4 correlates with a worse pathology outcome 
confirming a protective role not only for ACKR2, but also for other atypical 
chemokine receptors involved in chemokines control [75, 76]. ACKR2 genetic 
polymorphisms are predictors for the clinical response in patients with breast cancer. 
One single nucleotide polymorphism in the coding sequence (rs2228468) increases 
scavenger activity of chemokines and is correlated with increased relapse-free survival 
[77, 78]. The protective role of ACKR2 was also described in cervical squamous cell 
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cancer and in gastric cancer in which immunohistochemistry expression of ACKR2, 
ACKR1, and ACKR4 was correlated with a better outcome of the disease [79, 80]. 
Another contest in which ACKR2 has a protective role is human lung cancer. The lung 
cancer cell line A549 over-expressing ACKR2 showed an inhibition of in vitro 
proliferation and in vivo tumor growth caused to enhanced scavenger activity by the 
receptor [81]. These results indicate that ACKR2 expression by cancer cells limits 
tumor growth through regulation of leukocytes recruitment. Limited and not well 
exhaustive data have explored the role of ACKR2 expressed by stromal tumor cells 
such as lymphatic vessel on carcinogenesis [39]. 
 
1.4 Neutrophils 
Neutrophils are the most abundant circulating leukocytes in human (50 – 70% of 
neutrophils on total leukocytes) and have an estimated half-life of 7 hours in blood and 
1 – 2 days in tissue. Neutrophils play a central function in recognition, phagocytosis 
and killing of pathogens through production of reactive oxygen species (ROS), 
degranulation of antimicrobial peptides and the formation of neutrophil extracellular 
traps (NETs) [82]. In addition to the role in the innate response against pathogens, 
neutrophils play a role also in the regulation and activation of the innate and adaptive 
immunity [83] and in several pathological diseases including cancer [82, 84]. In the 
cancer contest, neutrophils were considered neutral players for several years but in the 
last decade, neutrophils were described to have both pro-tumoral and anti-tumoral 
functions depending on the activation and polarization state [10, 85]. Clinical data 
indicate that circulating and infiltrating neutrophils have a predicting role about 
patients survival. Elevated neutrophil-to-lymphocytes ratio (NLR) is considered a poor 
prognostic indicator in various cancer type [86]. Moreover, a meta-analysis indicates 
neutrophils presence in tumor tissue associated with poor prognosis [87]. 
 
 Neutrophil polarization in cancer 
Neutrophils are involved in several pathological contexts including cancer [84]. Even 
if neutrophil infiltration constitutes an important portion of all infiltrating leukocytes 
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in many tumor types [87], only recently the neutrophils role in cancer was starting to 
be elucidated. It was demonstrated for the first time by Fridlender and colleagues in 
1999 that neutrophils have a double role in cancer [85]. In this paper TANs were 
classified in two functional states: pro-inflammatory and anti-tumoral (N1) or anti-
inflammatory and pro-tumoral (N2) [85]. Neutrophil polarization is due to cytokines 
present in the tumor microenvironment: IFN-b polarized TAN to N1 phenotype while 
TGF-b or the inhibition of IFN-b cause a polarization toward an N2 phenotype [88]. 
The main morphological feature of N1 neutrophils is the hypersegmented nucleus. N1 
status is associated to production of pro-inflammatory cytokines (e.g. TNF-a) and 
ROS, expression of ICAM-1 and low levels of CD62L. From a functional point of 
view, N1 neutrophils are able to stimulate T cell responses and to kill cancer cells (Fig. 
1.6). On the other hand, N2 neutrophils show a ring-like nucleus, they are negative for 
ICAM-1 and express at high level of CD62L; they exert their pro-tumoral role 
expressing MMP9 and VEGF (Fig. 1.6) [84, 89]. Little is known about neutrophils 
plasticity. It is supposed that TANs that infiltrated tumor in early stages have N1 
phenotype and during tumor progression they are polarized toward N2 phenotype. In 
mice injected with Lewis Lung Carcinoma (LLC) and mesothelioma (AB12), TANs 
at early stages show N1 markers, produce high level of TNF-a and NO and have 
increased cytotoxic activity toward cancer cells, while in later stages neutrophils 
acquire pro-tumoral features [90]. The same feature was found in a model of breast 
cancer liver metastasis, in which TAN acquire N2 phenotype during progression and 
have pro-tumoral functions [91]. Also in human lung cancer TAN show in the early 
phase of the disease an activated phenotype (ICAM-1+/CD62Llow), express a broad 
group of chemokine receptors (CCR5, CCR7, CXCR3, and CXCR4), produce pro-
inflammatory cytokines and chemokines (CCL2, CXCL8, CCL3 and IL-6) and 
stimulate T cell proliferation through costimulatory molecules [92]. While at the 
moment the neutrophil polarization concept is supported by several evidences in many 
cancer type, it is not well elucidated if neutrophils phenotype changes during tumor 
progression or different neutrophil subsets are recruited during tumor growth [10]. In 
the next paragraph, neutrophil pro-tumoral and anti-tumoral activities will be 
discussed. 
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Figure 1.6: Neutrophil polarization in cancer. N1 phenotype is induces by IFN-b 
activity and N2 phenotype is induces by TGF-b: N1 and N2 are differentiates by shape 
of the nucleus, surface markers, production of inflammatory mediators and 
chemokines and by the expression of chemokine receptors [10]. 
 
 Neutrophil pro-tumoral role 
Neutrophils in cancer can exert pro-tumoral and anti-tumoral functions [84]. Several 
data elucidate the mechanisms of their pro-tumoral functions. TANs are able to release 
enzymes contained in their granules such as neutrophil elastase (ELA2), neutrophils 
collagenase (MMP8) and neutrophils gelatinase B (MMP9) that allow tumor cells 
invasion by remodeling extracellular matrix (ECM) [93]. Neutrophils support tumor 
growth secreting cytokines and growth factors (EGF, TGF-b, PDGF, HGF, VEGF). In 
detail, hepatocyte growth factor (HGF) is described to promote invasion of human 
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pulmonary adenocarcinoma cells [94] and VEGF production is enhanced through the 
oncostatin M production [95, 96]. Moreover, granule enzymes are able to activate pro-
angiogenic factors EGF, TGF-b, and PDGF from ECM [97]. ROS and reactive 
nitrogen species (RNS) are described to enhance tumorigenesis contributing to damage 
DNA and promote genetic instability [98]. ROS in the same time display anti-tumoral 
activity inhibiting metastatic seeding [99, 100] as discussed in the next paragraph. 
Direct promotion of cell proliferation is exerted by ELA2, prostaglandin E2 (PGE2) 
and leukotrienes [101, 102]. In particular, leukotrienes are implied in proliferation of 
metastasis initiating cells in different preclinical model of breast cancer [103]. 
Neutrophils dampen T cell cytotoxic activity through iNOS secretion after stimulation 
by IL-17 and G-CSF produced by gd T cells [104]. As discussed above, neutrophils 
are able also to form NETs upon activation and cancer cells can be trapped in the net 
and increase their adhesion to hepatic and pulmonary microvasculature causing 
metastasis [105]. Moreover, neutrophils exert indirect tumor growth inhibiting anti-
tumoral immune responses through production of arginase 1 (Arg-1) dampening T cell 
function upon CXCL8 stimulation [106], expressing programmed death-ligand 1 (PD-
L1) [107] and producing CCL2 and other chemokine that enhance recruitment of other 
tumor-supporting leukocytes [108]. 
 
 Neutrophil anti-tumoral role 
Limited compared the pro-tumoral functions, but promising evidences indicate the 
neutrophils anti-tumoral role. As discussed above, ROS promote tissue damage and 
cell death but in same time, ROS have a direct cytotoxic effect against tumor cells [99, 
100]. Neutrophils can inhibit the lung metastatic seeding in a preclinical breast cancer 
model trough the generation of hydrogen peroxide [109]. Another mechanism of 
cancer cell killing includes antibody-dependent cell-mediated cytotoxicity (ADCC) 
[110] and this process is important for anticancer monoclonal antibodies based 
therapies [111]. In addition, interferon-activated neutrophils are able to produce TNF-
related apoptosis inducing ligand (TRAIL/APO2 ligand) with selective apoptotic 
activity against tumor cells [112, 113]. Neutrophils are also able to enhance Fas-
mediated apoptosis [114]. MET, a proto-oncogene involved in cancer cell-cycle and 
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survival, is expressed by TANs after TNF-a stimulation. Its genetic ablation leads to 
decreased transmigration across endothelium and dampen nitric oxidase-dependent 
tumor cell killing that limit cancer cell growth [115]. Neutrophils are able to decrease 
uterine tumor development in pten-/- mice promoting tumor cell detachment [116]. 
Finally, neutrophils stimulate also adaptive immune response through the expression 
of costimulatory molecules. Neutrophil stimulate proliferation of CD4+ and CD8+ T 
cells through expression of OX-40L and 4-1BBL increasing their cytotoxic activity in 
early stage of human lung cancer [92]. Recently, a neutrophil subpopulation in lung 
cancer was discovered. It was defined as APC-like hybrid TANs due to the expression 
of costimulatory molecules and because it stimulates antigen non-specific T cell 
response [117]. Enhancing of anti-tumoral neutrophil functions is a potential 
immunotherapy approach that unleash neutrophils cancer cell killing ability. 
 
 Neutrophil subpopulations 
Neutrophils were considered for many years a homogeneous population among 
granulocytes, but several evidences indicate the presence of neutrophil subsets in 
inflammation and in cancer both in mice and human. Circulating neutrophils in healthy 
mice are mainly Ly6G+/CD62high/ICAM-1neg but during inflammation it was observed 
a fraction of circulating neutrophils that upregulated ICAM-1 and shed CD62L [118]. 
CD62L (also known as L-selectin) is a cell adhesion molecule normally expressed by 
neutrophils and lymphocyte subsets [119]. CD62Llow neutrophils were associated with 
an aged phenotype with higher expression of CXCR4, TLR4, CD11b, CD49 and 
ICAM-1 exhibiting an increased aMb2/Mac1 integrin activation and NET formation 
in inflammatory conditions [120]. In homeostatic conditions, also human circulating 
neutrophils are described as a unique population labelled as CD16high/CD62Lhigh, but 
in inflammatory conditions other two populations were described: CD16dim/CD62Lhigh 
that are freshly released from bone marrow or young neutrophils and 
CD16high/CD62Llow that are older and have increased anti-microbial function and 
produced higher amount of ROS [121]. CD16high/CD62Llow neutrophil subpopulation 
was further described to upregulate CD11b and CD11c with improved suppression of 
T cell proliferation [122, 123]. In human and mouse during inflammation, a neutrophil 
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subpopulation was also described for its ability to reverse transmigrate from tissue to 
blood. These neutrophils are called reverse transmigrated neutrophils (rTEM) and 
showed activated phenotype in terms of expression ICAM-1, ROS production and low 
level of CXCR1 [124]. rTEM role is not completely elucidated because they can 
potentially spread the inflammation to distal organs form the site of inflammation 
[125], but in a zebrafish model rTEM are described dampening inflammation [126]. 
Another neutrophil subset was described in humans and mice for its ability to produce 
pro-angiogenic factors, in particular VEGF-A, the expression of VEGFR1, CD49d 
(VLA4), high level of MMP9 and CXCR4 [127]. CD10, normally expressed by 
neutrophils, has been indicated as marker of mature neutrophils. CD10 negative 
neutrophils have an activated phenotype, they able to stimulate T cell proliferation and 
IFN-g production [128]. As discussed above, a subpopulation of APC-like hybrid 
TANs has been recently described in lung cancer but it is not known if they are CD10 
negative [117]. Finally, in cancer patients and tumor-bearing mice neutrophil subsets 
can be identified on the basis of their density. Indeed, Sagiv et colleagues identified 
immature low-density neutrophils (LDNs) and mature high-density neutrophils 
(HDNs). LDNs and HDNs, in addition to be different in terms of density and shape, 
have different functional roles: HDNs have increased cancer cell killing activity while 
LDNs have an immunosuppressive role resembling features of granulocytes – myeloid 
derived suppressor cells (G-MDSC) [129]. Collectively taken, redundant and not 
officially adopted nomenclature of neutrophil subsets create a confused classification. 
Further efforts will be necessary to better describe neutrophil subsets linking 
functional activity and markers expression in order to create a unique nomenclature. 
This will be useful to describe neutrophil heterogeneity among different diseases 
underlying common features that summarize neutrophil biology. 
 
 Chemokines in neutrophil polarization 
As discussed above chemokines and chemokine receptors are mediators of the 
inflammation and play a key role in physiological and pathological contexts including 
cancer. Neutrophils express both chemokines and chemokine receptors as regulators 
of fundamental biological and functional processes including mobilization, 
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transmigration and cell activation [130, 131]. In this paragraph, it will be discussed the 
role of CXC and CC chemokines in neutrophil biology in cancer. 
 
 CXC chemokines and related receptors 
Neutrophils express high level of CXCR1 and CXCR2 and, after binding with their 
ligands, they induce a strong migrating effect [131]. In cancer, agonist of CXCR1 and 
CXCR2 such as CXCL8, CXCL5 and CXCL6, are produced by cancer cells causing 
neutrophils mobilization and infiltration into tumor mass. At the same time, 
neutrophils are able to produce and release chemokines, for example CXCL2, that 
contribute to sustain tumor infiltration by neutrophils. The most abundant chemokine 
produced by tumoral cells is CXCL8; it is over-expressed by many tumors type such 
as colon, lung, prostate, ovarian carcinoma and melanoma [132]. CXCL8 is not only 
associated with promotion of inflammation and neovascularization [133], but also with 
neutrophil-dependent cell mutation that leads to tumorigenesis [134]. On the same 
way, CXCL5 is described to be involved in tumor progression and metastasis in several 
cancer types [135, 136]. CXCL5 was found to recruit pro-tumoral neutrophils in 
preclinical models of hepatocellular carcinoma (HCC) [137] and intrahepatic 
cholangiocarcinoma (ICC) [138]. Also in human, CXCL5 expression correlates with 
poor prognosis in HCC and ICC patients [138]. Furthermore, CXCL6, CXCL2 and 
CXCL1 are involved in neutrophil recruitment to tumor. CXCL6 induce neutrophil 
infiltration sustaining tumor angiogenesis [139] and tumor growth in melanoma [140]. 
CXCL1 and CXCL2 were found to recruit neutrophils expressing S100A8 and 
S100A9 that increased cancer cell survival and resistance to chemotherapy [141]. In 
line with these results, genetic deletion of CXCR2 inhibited neutrophil recruitment 
into the tumor, inhibited tumor growth and reduced angiogenesis in B16F10 and 
MCA205 tumor models [142]. On the contrary, the role of CXCR2 in metastasis is not 
fully elucidated. In renal cell carcinoma (RCC) CXCR2 ligands CXCL5 and CXCL8 
produced by cancer cell are able to recruit anti-metastatic neutrophils that inhibit 
cancer cell seeding [143]. It is not known if CXCR2, beside allowing recruitment of 
circulating neutrophils, is differentially expressed by neutrophil subpopulations and 
has a role in their functional activities. Treatment with IFN-b, a N1 polarizing 
cytokine, does not modulate CXCR2 expression in murine neutrophils [142], while in 
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N1 TANs in lung cancer patients CXCR2 is down regulated [92]. Moreover, CXCR1 
is downregulated in rTEM [124] during inflammation but no evidence indicates 
chemokine receptors modulation on rTEM in cancer. Neutrophils express also CXCR4 
and its ligand CXCL12 (also known as SDF-1) that negatively regulate neutrophils 
release from BM. Hematopoietic progenitors express high levels of CXCR4 and it is 
downregulated during maturation. Circulating neutrophils express low levels of 
CXCR4 and it is further downregulated by a panel of cytokine including IFN-g, IFN-
a, granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF [144]. 
CXCR4 is upregulated in senescent neutrophils and promote their recalling to BM 
[145]. In the tumor context, CXCR4 was found upregulated in a subset of circulating 
neutrophils promoting angiogenesis and tumor progression [127]. CXCR4 is also 
inhibited by IFN-b suggesting its expression as N2 marker [89]. Pharmacological 
inhibition of CXCR4 through administration of AMD3100 (also known as Plerixafor), 
increased anti-tumoral immune response in murine models of hepatocellular 
carcinoma inhibiting immunosuppressive microenvironment [146]. However, being 
CXCR4 highly expressed also by tumor cells, it is difficult to extrapolate its role in 
neutrophil function and polarization. 
 
 CC chemokines and related receptors 
Circulating neutrophils from healthy individuals express low level of CC chemokine 
receptors and for this reason their role in neutrophil biology is not fully understood 
[147, 148]. For example, the role of CCR2 in neutrophils is emerging only recently. 
Neutrophils express lower CCR2 levels compared to monocytes, but Fujimura and 
colleagues found that CCR2 is important for neutrophil mobilization from BM [149] 
and it is responsible for neutrophil accumulation in a model of rheumatoid arthritis 
(RA) [150]. Upregulation of CCR1, CCR2, CCR3, CCR5 enhances the respiratory 
burst for bacterial killing [147] and CCR2-depend ROS generation has an anti-
metastatic role through direct cancer cell killing [109]. On the other hand, neutrophils 
producing the CCR2 ligand CCL2, enhances the recruitment of CCR2 positive 
leukocytes that can have a pro-tumoral role [108]. Neutrophil CCR5 expression is also 
associated to enhanced recruitment of myeloid cells with immunosuppressive role that 
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sustain tumor growth [151]. Collectively taken, CC chemokine receptors can be 
considered markers of activated neutrophils or N1 phenotype and could be potential 
target to enhance anti-tumor responses. On the other hand, expression of CC 
chemokine receptor ligands are markers of a N2 phenotype. This address a complex 
role for CC chemokines and their receptors. While CC chemokine receptors can trigger 
anti-tumoral function of neutrophils, their ligand could at the same time enhance 
recruitment of other pro-tumoral leukocytes (Fig. 1.6) [10]. 
 
1.5 Breast cancer 
Breast cancer represents the second common female tumor and counts about 25% of 
all tumor types. The estimated incidence rate is 19.4 per 100,000 people in East Africa 
and 89.7 per 100,000 in West Europe (WHO, 2015) [152]. Breast cancer includes a 
wide range of tumor of the breast with different anatomical and molecular 
characteristics [153]. Histological classification divides breast cancer in “in situ” and 
invasive (infiltrating) carcinoma. In situ carcinoma can be sub-classified in ductal or 
lobular carcinoma depending on tissue of origin. Invasive carcinoma is further sub-
divided in tubular, ductal lobular, invasive lobular, infiltrating ductal, mucinous and 
medullary [154]. Breast cancer heterogeneity encloses also differential expression of 
molecular marker belonging to hormone receptors and oncosuppressor genes. Tumors 
are classified depending on the expression of estrogen receptor (ER), progesterone 
receptor (PR), ErbB2 (Her2/neu), epidermal growth factor receptor (EGFR) and p53. 
Based on molecular expression, breast cancer is subdivided as: basal like (that includes 
triple negative breast cancer, ER, PR and Her2 negative, ErbB2+), normal breast 
cancer, luminal subtype A, luminal subtype B (further subdivided in Her2 positive and 
negative) and claudin-low (Fig. 1.7) [154]. Pharmacological therapy based on 
hormone receptors expression represents an efficacious therapy strategy being 
molecular heterogeneity an important feature within cancer with the same histological 
classification that predicts clinical outcome [155]. As discussed below, immune 
system plays a central role in breast cancer and immunotherapy emerges as a concrete 
therapeutic approach in the treatment of this pathology [156-158]. 
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Figure 1.7: Molecular classification of breast cancer [154]. 
 
 The immune system in breast cancer  
Immune system plays a crucial role in breast cancer biology [159]. Leukocytes 
infiltrate breast cancer since the first phases of the pathology and co-evolve with 
disease progression [156]. In the initial phase, leukocytes are able to fight against 
tumor cells, but mechanism of immune escape and immunosuppression exerted by 
cancer cells cause a switch in leukocytes activity that limit their cancer cell killing 
activity, sustain primary tumor growth and contribute to metastasis spread [156]. Both 
innate and adaptive cells infiltrate tumor tissue and exert a role in cancer biology. 
Referring to innate immunity, macrophages have a paradigmatic role in disease 
progression [160]. Early phases of the disease are associated to the anti-tumoral M1 
macrophage phenotype, while established tumors are associated to pro-tumoral and 
pro-metastatic M2 phenotype. Targeting of TAM represents a valid therapeutic option 
to prevent M2 and M2-like polarization that promote tumor growth [161, 162]. Mast 
cells were observed infiltrating breast cancer and are implied directly and indirectly in 
angiogenesis [163] while eosinophils were not found infiltrating the tumoral mass 
[164]. Referring to adaptive immunity, the presence of tumor infiltrating lymphocytes 
(TILs) is correlated with negative axillary nodal status, smaller tumor size, and lower 
grade [165]. Among TILs there are both pro and anti-tumoral cells. The positive effects 
on disease progression have to be attributed to CD4+ Th1 Tcells and CD8+ T cells. 
On the other hand, CD4+ Th2 T cell and CD4+ regulatory cells (T reg) have a pro-
tumoral role and suppress immune response and lead to tumor growth [156]. Breast 
cancer can be considered as a good example of cancer immunoediting. Cancer cells 
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downregulate MHC-I molecule and at the same time overexpress check point 
inhibitors such as PD-L1 that cause evasion and dampening of the immune system, 
respectively [156]. Many immunotherapeutic strategies are proposed to enhance 
immune response against breast cancer. The most used strategy is focused on 
monoclonal antibody (for example trastuzumab that impairs HER2 signaling) and 
immune check point inhibitors alone or in combination with surgery ablation, 
radiotherapy, chemotherapy or hormonal therapy. Promising but more technical 
challenge approach, such as adoptive T cell therapy and vaccines, are also under 
clinical evaluation [157, 166]. 
 
 Neutrophils in breast cancer 
Neutrophils exert both pro-tumoral and anti-tumoral functions as described above 
depending on the tumor microenvironment [10]. In breast cancer context, several 
evidence indicates a key role of neutrophils in primary tumor growth and metastasis 
dissemination. In patients, high NLR is associated to poor overall survival (OS) and 
disease-free survival (DFS) [167, 168]. Among the different cancer subtype, high NLR 
is associated to reduced OS in luminal A subtype [167] and in ER and HER2 negative 
tumors [168]. Using Polyoma Middle T (PyMT) model it was demonstrated that 
neutrophilia is caused by G-CSF production by cancer cells [169]. In breast cancer 
patients there is a circulating neutrophil subpopulation displaying an 
immunosuppressive phenotype that sustain tumor growth [129]. Collectively taken, 
both increased number and altered phenotype of circulating neutrophils correlate with 
pathology outcome. Several evidence indicates a key role of neutrophils in breast 
cancer metastasis exerting both anti-metastatic and pro-metastatic role [170]. The anti-
metastatic role was described by Granot and colleagues. They found that the secretion 
of cytokines and chemokines such as CCL2 by cancer cells directly activates 
neutrophils to kill tumor cells by ROS production [109]. MET was described to 
enhance neutrophil extravasation with anti-tumoral and anti-metastatic activities 
[115]. On the contrary, many evidence indicates a pro-metastatic role of neutrophils. 
Coeffelt and colleagues have observed that the production of iNOS by neutrophils, 
induced by IL-17 secreted by gd T cells, inhibits CD8 T cells activity [104]. 
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Neutrophils can have a direct effect of metastasis acting on the pre-metastatic niche 
[103] trapping cancer cells through the formation of NET [171]. Mechanisms of 
recruiting pro-metastatic neutrophils are IL-5 and GM-CSF in obesity conditions 
[172], IL-16 [173]. and TNF-a that recruits CXCR2+ neutrophils [174]. Neutrophils 
interact with other immune cells involved in metastasis control such as NK cells. In 
4T1 model, neutrophils are described to inhibit NK cells and promote tissue 
remodeling thus facilitating metastasis seeding [175]. Collectively taken, immune cells 
and in particular neutrophils, play a key role in breast cancer biology. Targeting of 
neutrophils represents a potential approach to limit disease progression in particular 
metastasis spread. 
 
1.6 Glioma 
Glioma represents about 80% of malignant brain tumors with an estimated annual 
incidence of 6.6 per 100,000 individuals in the USA. The traditional classification 
divided glioma into four major histological classes (grades I–IV), taking count of their 
microscopic characteristics (for example cytological atypia, anaplasia, mitotic activity, 
microvascular proliferation, and necrosis) and clinical behavior. In 2016 World Health 
Organization (WHO) revised Classification of tumors of the central nervous system 
(CNS) [176]. The new classification also dived tumors in: astrocytomas (WHO grade 
I–IV), oligodendrogliomas (WHO grade II–III) and mixed oligoastrocytomas (WHO 
grade II–III) depending on their putative cells of origin. Grade IV glioma or 
Glioblastoma (GBM) have the higher incidence among primary brain tumor and have 
a lifespan from 12.2 to 18.2 months with a 5-year survivor rate less than 5%. GMB 
classification takes also advantage of molecular classification: IDH mutations, 1p and 
19q co-deletion, methylation status [177]. Lower-grade gliomas (WHO grade II–III) 
are about 30% of all glioma and less aggressive and the clinical behavior is not 
predictable based on their histologic class [176]. 
GBM care protocol is not changed in the last 10 years and consists of maximal tumor 
rejection followed by radiotherapy and chemotherapy with Temozolomide [178]. 
Lower-grade glioma therapeutic protocol consists of surgical rejection, clinical 
monitoring, radiation alone or in concomitant with chemotherapy. Therapy protocol 
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depend on histologic class, grade and molecular features (IDH mutations, 1p and 19q 
co-deletion). New therapeutical strategies were tested in these years to try to prolong 
patients survival, but clinical trials based on blocking angiogenesis [179] and targeting 
dysregulated cell signaling pathways [180] failed to increase survival. 
In the last 5 years, many successful data in the battle against cancer come from 
immunotherapy [181-183]. Due to the fact that in glioma there is a strong 
immunosuppressive microenvironment, unleashing the immune response against 
cancer could be a potential efficacious treatment also for this tumor [184]. 
 
 The immune system in glioma 
Traditionally CNS was described as an immune-privileged site due to the presence of 
the Blood-Brain Barrier (BBB) and the absence of leukocytes and lymphatic vessels. 
These was demonstrated with preclinical models of tissue engraftment in the brain that 
lack of the rejection due to immune response. However, it is becoming clear that the 
CNS actively interact with immune cells also in presence of an intact BBB [185, 186]. 
Moreover, Louvenau et al demonstrated the presence of lymphatic vessels within the 
dural sinuses. These vessels are able to transport leukocytes between cerebrospinal 
fluid and deep cervical lymphatic vessels [187]. In glioma context, disruption of BBB 
cause an important interaction between glioma cells and the immune system and the 
establishment of an immunosuppressive microenvironment that dampen cell-mediated 
immunity (Fig. 1.7) [188]. Immunosuppression is caused by glioma cells that over-
express molecules with immunosuppressive function such as E2, TGF-b, indoleamine 
2,3-dioxygenase (IDO), and IL-10. These molecules cause recruitment of T regulatory 
and myeloid derived suppressor cells to the tumor site that dampen APC presentation 
activity and T cell cytotoxic activity. Other mechanisms of immunosuppression occur 
in glioma; glioma cells downregulate their MHC-I complex provoking tumor escape 
and express PD-L1, ligand of PD-1 that inhibit MHC signaling limiting PD-1+ cells 
cytotoxic activity [189-191]. Blocking of PD-1 is considered a potential 
pharmacological effect to enhance T cell cytotoxic activity against cancer cells. In 
glioma preclinical models, the survival rate is increased after administration of a-PD-
1 in combination with radiotherapy [192]. Concomitant treatment with a-CTLA-4 and 
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a-PD-1 shows further increase in survival rate with increased number of activated 
CD8+ and NK cells and the decrease immunosuppressive cells in the lesion [193]. 
Moreover, concomitant pharmacological blocking of CTLA-4, PD-1 and IDO 
increased survival rate in other glioblastoma models confirming previous data. 
Blocking of CTLA-4 alone, and CTLA-4 and administration of IL-12 provoked an 
increase of tumor infiltrating effector T cell and decreased T regulatory infiltration 
[194-196]. Several clinical trials are ongoing to test the efficacy of checkpoint 
inhibitors in glioma patients. In addition other strategies to improve the immune anti-
tumoral response including vaccination with tumor-specific, tumor-associated 
peptides, infusion of primed autologous APCs and adoptive transfer of engineered T 
cell are under evaluation [197]. Also, myeloid cells in glioma are potential targets to 
improve immune response because TAMs are described as the main infiltrating 
leukocytes in glioma. Pharmacological inhibition of CSF-1R (CD115) that blocks 
monocyte maturation and differentiation toward an M2-like phenotype that sustains 
tumor growth, increases survival rate in a GMB mouse model [198, 199]. Neutrophils 
are able to infiltrate glioma lesion [200, 201] and could have both pro-tumoral and 
anti-tumoral functions.  
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Figure 1.8: The immune response in glioma. Glioma cells secrete TGF-b and IL-10 
promoting an immunosuppressive microenvironment that inhibit immune response 
against tumor cells [188]. 
 
 Neutrophils in glioma 
In glioma context, neutrophil role is not completed elucidated [188, 199]. Evidence 
coming from patients indicates an alteration of circulating neutrophils and the presence 
of TANs into brain lesion. It is reported that glioma patients have a strong neutrophila 
[202] due to massive production of G-CSF by the tumor [203, 204]. In glioma patients 
the neutrophil-to-lymphocytes ratio (NLR), that indicates neutrophilia normalized on 
lymphocytes count [86], is predictive of their outcome. Glioma patients with an NLR 
higher than 4 develop a worse outcome independently that NLR is measured before 
therapy [205, 206], after second surgery [207] and after treatment with temozolomide 
and radiotherapy [208]. On the other hand, NLR minor than 4 is associated to favorable 
outcome of the disease only in glioblastoma with wild type gene IDH1 that is one the 
most frequently mutated gene in GBM [209]. The upregulation of CD11b expression 
in neutrophils of GBM patients is an early sign of tumor progression [210]. Neutrophils 
participate in tumor growth maintaining an immunosuppressive microenvironment 
through the production of arginase I [211]. Bevacizumab treatment (anti-VEGF-A) is 
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more efficacious in patients with higher baseline neutrophil count and the TGCA 
database indicates that Csf3 expression is correlated with VEGF-A dependent 
angiogenesis (Fig. 1.9) [212]. Neutrophils can infiltrate also brain tumor lesion [200]. 
NRL is correlated with infiltrating neutrophils [213] and there is a positive correlation 
between glioma grade and anti-VEGF-A efficacy in GBM [200, 214]. Neutrophils are 
recruited to tumor site by CXCL8 produced after FasL triggering by glioma cells [215, 
216]. Neutrophils exert their immunosuppressive role in the lesion also when they are 
attracted by macrophage migration inhibitory factor (MIF) produced by cancer cells 
[217], inducing proliferation of cancer cells through the secretion of S100A4 [214] and 
contributing to the resistance to anti-angiogenic therapy (Fig. 1.9) [218]. Preclinical 
data confirm the pro-tumoral role of neutrophils. Neutrophil depletion in a glioma 
model through the administration of anti-Ly6G prolong mice overall survival [219]. 
Finally, IDH-1 mutant glioma showed a longer survival rate compared to wild type 
IDH-1 with a reduced neutrophil infiltration [220]. 
Preclinical glioma models are valid approach to study immune system in glioma but 
there is an important limitation due to the inverted leukocytes formula in mice (10 – 
25% of neutrophil on total leukocytes) compared to human (50 – 70% of neutrophil 
on total leukocytes). Preclinical data could underestimate the role of neutrophils in 
humans and necessitate a better characterization of circulating and infiltrating 
neutrophils in human samples [188]. 
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Figure 1.9: Neutrophils in gliomas. A) Circulating neutrophils upregulate CD11b as 
early sign of tumor progression, express Arg-1 and VEGF-A that sustain angiogenesis. 
B) Infiltrating neutrophils are recruited to the tumor site through MIF and CXCL8 
secretion by cancer cells and produce S100A4 that regulate cancer cell proliferation 
and elastase that promote cancer cell infiltration in healthy tissue [188]. 
  
 
LEGEND 
 Neutrophil 
  Lymphocyte 
 Cancer Cell 
   CD11b 
Tumor progression 
ARG-1 
B) Infiltrating 
Neutrophils 
A) Circulating  
Neutrophils 
Immunosuppression 
ELASTASE 
Infiltration 
S100A4 
Proliferation MIF  
CXCL8 
Recruitment 
VEGF-A 
Angiogenesis 
 35 
2 AIM OF THE THESIS 
The general aim of this PhD thesis was to investigate the role of the atypical chemokine 
receptor ACKR2, a scavenger for inflammatory CC chemokines, in cancer. 
In particular, being ACKR2 protective in chronic inflammation and in the extrinsic 
pathway of cancer, the first objective was to assess the role of ACKR2 in the intrinsic 
pathway of cancer development, using both the HER2 oncogene-driven breast cancer 
model NeuT and orthotopical and intravenous injection of the breast cancer 4T1 and 
melanoma B16F10 cell lines. The objective was to determine if ACKR2 has a role in 
primary tumor growth and lung metastasis development elucidating the role of innate 
immune cells, monocytes and neutrophils. 
The second objective was to study by flow cytometry the phenotype of circulating and 
infiltrating monocytes and neutrophils in high grade glioma patients, a tumor 
characterized by neutrophilia and immunosuppression, in order to understand the 
prognostic role of these cells. 
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3 MATERIAL AND METHODS  
 
3.1 ACKR2 study material and methods 
 
 Cell lines 
4T1 and 4T1-66cl4 cells (kindly provided by Dr Claudia Chiodoni, Department of 
Experimental Oncology and Molecular Medicine, Istituto Nazionale dei Tumori, 
Milano, Italy) were grown in DMEM (Lonza) supplemented with 10% FBS (Sigma), 
1% penicillin/streptomycin (Lonza), 1% L-glutamine (Lonza), 1% sodium pyruvate 
(Lonza), 1% Hepes (Lonza). B16-F10, kindly provided by Massimiliano Mazzone 
(Vesalius Research Center, Leuven, Belgium), were grown in DMEM (Lonza) 
supplemented with 10% FBS (Sigma), 1% penicillin/streptomycin (Lonza), 1% L-
glutamine (Lonza). 4T1-luc from PerkinElmer were grown in RPMI 1640 (Lonza), 
10% FBS (Sigma), 1% penicillin/streptomycin (Lonza), 1% L-glutamine (Lonza), 1% 
sodium pyruvate (Lonza), 5.4 g/l glucose (Sigma). 
 
 Animals 
Ackr2-/- mice were maintained on pure Balb/c and C57BL/6J genetic background. 
Balb/c WT and Ackr2-/- mice were crossed with NeuT mice (kindly donated by 
Professor Federica Cavallo, University of Turin, Italy). WT and WT CD45.1 mice 
were obtained from Charles River Laboratories (Calco, Italy) or were cohoused 
littermates. All colonies were housed and bred in the SPF animal facility at Humanitas 
Clinical and Research Center in individually ventilated cages. Mice used for 
experiments were 8 to 12 weeks old. Procedures involving animals handling and care 
were conformed to protocols approved by the Humanitas Clinical and Research Center 
(Rozzano, Milan, Italy) in compliance with national (4D.L. N.116, G.U., suppl. 40, 
18-2-1992) and international law and policies (EEC Council Directive 2010/63/EU, 
OJ L 276/33, 22-09-2010; National Institutes of Health Guide for the Care and Use of 
Laboratory Animals, US National Research Council, 2011). The study was approved 
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by the Italian Ministry of Health (approval n. 88/2013-B, issued on the 08/04/2013). 
All efforts were made to minimize the number of animals used and their suffering. 
 
 Tissue collection 
Blood was collected from the retro-orbital plexus and by cardiac puncture as described 
[221]. Briefly, blood was collected in 2KD-EDTA spray coated tubes (BD 
Bioscience), washed in FACS buffer (PBS-/-, 1% BSA, 0.05 % sodium azide), red 
blood cells were lysed, washed again and cells were stained as indicated. Lungs were 
instilled with PBS for FACS analysis or 10% neutral buffer formalin for histological 
analysis. For FACS analysis, lungs were minced, digested for 45 min in 1 mg/ml 
collagenase IV (Sigma) in PBS-/- (Sigma), filtered with 70 µm cell strainer. Red blood 
cells were lysed and cells stained as indicated. BM was collected by femurs. Bones 
were harvested, cleaned, flushed and filtered with 70 µm cell strainer. Red blood cells 
were lysed and cells stained as indicated below. 
 
 Tumor models 
Tumor volume was assessed with caliper using the formula: (Length x Width x 
Width)/2. Tumor take in NeuT model was determinate by palpation as number of 
mammary tumors per mouse. For 4T1 and 4T1-66cl4 models 5 x 105 cells were 
injected in the mammary fat pad of Balb/c mice. For lung metastasis evaluation in 
NeuT, 4T1 and 4T1-66cl4 model, lungs were instilled and fixed for 24 h with 4% 
neutral buffered formalin, routinely processed for paraffin embedding, sectioned at 4 
µm thickness, and stained with hematoxylin and eosin. Sections were evaluated in a 
blinded fashion under a light microscope. Lung metastasis in NeuT, 4T1 and 4T1-
66cl4 models were classified according to their size into: small (<30 neoplastic cells), 
medium (30–300 neoplastic cells), and large (>300 neoplastic cells). A total metastatic 
score was then calculated for each lung as follows: number of small metastases*1 + 
number of medium metastases*3 + number of large metastasis*5. Representative 
images were acquired with Slide Scanner VS120 dotSlide (Olympus) and analyzed 
with ImageJ. The melanoma cell line B16F10 (2 x 105 cells) was injected i.v. in 
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C57BL/6 mice and metastases were macroscopically counted as dark nodules on the 
lung surface. For all the models, metastatic ratio was calculated as ratio of metastasis 
in Ackr2-/- or depleted mice compared to indicated control mice. For macrophages 
depletion, mice were treated with 100 µg of a-CD115 antibody (clone AFS98, 
Bioxcell) the day before 2 x 105 B16-F10 injection and every two days for the entire 
duration of the experiment. For neutrophils depletion, mice were treated with 200 µg 
of a-Ly6G antibody (clone 1A8, Bioxcell) the day before 2 x 105 B16-F10 injection 
and with 100 µg every three days for the entire duration of the experiment. For B cell 
depletion, mice were treated with 250 µg of a-CD20 (clone 5D2, Genentech Inc.) three 
days before 2 x 105 B16-F10 injection. For adoptive transfer experiments, neutrophils 
were isolated from WT and Ackr2-/- BM using the Mouse Neutrophil Isolation Kit 
(Miltenyi Biotec) and an autoMACS Pro separator (Miltenyi Biotec). Cell purity was 
assessed by flow cytometry (CD45, CD11b, Ly6G) and used only if neutrophils were 
≥ 95% on CD45+ cells. For B16F10 model, recipient WT mice were injected i.v. with 
5 x 106 WT or Ackr2-/- neutrophils every 3 days for the entire duration of the 
experiment. For adoptive transfer experiment, recipient CD45.1 mice were injected 
i.v. with 2 x 106 CD45.2 WT or Ackr2-/- neutrophils 15 minutes before CCL3L1 
(R&D) injection and after 1 hour lung and blood were collected and leukocytes 
counted by flow cytometry. 
 
 Immunohistochemistry 
Serial 4 µm formalin-fixed and paraffin-embedded lung sections were deparaffinized 
and underwent heat-induced epitope retrieval with pressure cooker. Endogenous 
peroxidase activity was blocked by incubating sections in 3% H2O2 for 15 min. Slides 
were rinsed and treated with Rodent Block M (Biocare Medical) for 30 min to reduce 
nonspecific background staining and then incubated for 1 h at room temperature with 
Ly6G antibody (1:200; clone 1A8; BD Bioscience), Sections were incubated for 30 
min with Rat on Mouse HRP-Polymer kit (Biocare Medical). The immunoreaction was 
visualized with 3,3’-diaminobenzidine (Peroxidase DAB Substrate Kit, Vector 
Laboratories) substrate and sections were counterstained with Mayer’s haematoxylin. 
Negative immunohistochemical controls for each sample were prepared by replacing 
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the primary antibody with normal serum. Positive control sections were included in 
each immunolabeling assay. Tissues were dehydrated with ethanol, mounted with 
Eukitt and acquired with an Olympus BX61 virtual slide scanning system using Cell^F 
software (Olympus). In each section 10 independent field of view were acquired. To 
evaluate the extent of granulocytes infiltration in the lung parenchyma, the percentage 
of Ly6G-positive area was analyzed with Image-Pro Analyzer 7.0 (Media Cybernetics) 
software. Representative images were generated using the ImageJ analysis program 
(http://rsb.info.nih.gov/ij/). 
 
 Flow cytometry analysis 
Flow cytometry analysis were performed as previously described [221]. To exclude 
death cells from analysis, cells were stained with Violet dead cell stain kit (Thermo 
Fisher). Single cell suspension was stained with antibodies listed in table 3.1 and 
related isotype. All antibodies were purchased from BD Bioscience, BioLegend, 
eBioscience or AbD Serotec. Flow cytometry data were acquired using a FACSCanto 
II (BD Bioscience) and LSR Fortessa (BD Bioscience) and data were analyzed with 
FACS Diva (BD Bioscience) and representative images were generated with FlowJo 
Software (Tree Star). To analyze ROS production, neutrophils were stained with 5 µM 
CellROX Deep Red Reagent (Thermo Fisher) for 20 min at 37°C in RPMI 1% FBS. 
Staining was blocked on ice, red blood cells were lysed, and neutrophils analyzed by 
flow cytometry within 2 h from the staining. The absolute number was determined by 
using TruCount beads (BD Biosciences) according to the manufacturer’s instructions. 
Cell sorting was performed using a FACSAria III (BD Bioscience). 
 
 Leukocyte mobilization 
Mice were injected i.p. with 3 µg CCL3L1 (R&D) and after 1 hour blood was collected 
and leukocytes counted by flow cytometry.  
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 Generation of BM chimeras 
Recipient mice received gentamycin (0.8 mg/ml) in drinking water for 2 weeks starting 
10 days before irradiation. WT and Ackr2-/- mice were lethally irradiated with a total 
dose of 900 cGy. After 2 h, mice were injected in the retro-orbital plexus with 4 x 106 
nucleated BM cells obtained by flushing of the cavity of a freshly dissected femur from 
WT or Ackr2-/- donors. Experiment were performed 16 weeks after irradiation to allow 
complete myeloid repopulation. 
 
 In vitro cell killing assay 
Neutrophils were isolated by magnetic separation as described above from blood of 14 
days 4T1 tumor-bearing mice or from BM of untreated mice and seeded (1 x 105/well) 
in a 96 wells plate in which, 4 hours before, 5 x 103 4T1-luc cells were plated in 
Optimem (Thermo Fisher) + 0.5% FBS. Cells were incubated overnight in presence of 
Apocynin 100 µM (Sigma) or DMSO control. Firefly luciferase activity was detected 
with luciferase assay system (Promega) and Synergy H2 (Biotek). Cell killing was 
calculated as percentage of tumor lysis by the following formula: % cell killing = (1 - 
[luminescence of samples with neutrophils] / [luminescence of samples in medium]) x 
100. 
 
 Transcript analysis by quantitative PCR (qPCR) 
Total RNA was extracted from neutrophils using the TRIzol reagent (Thermo Fisher). 
Reverse transcription was done using High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Quantitative PCR was performed with TaqMan Gene 
Expression Assays in a CFX Connect Real-Time PCR Detection System (BioRad) 
with probes listed in table 3.2. Relative mRNA expression was determined by using 
the 2^-DCt method, and normalized to the expression of the housekeeping gene Gapdh. 
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 Statistical analysis 
Data are represented as mean. In all figures sample variation is shown as SD. P value 
was generated using the unpaired t test (GraphPad Prism 5). * = p < 0.05, ** = p < 
0.01, *** = p < 0.001, ns = not statistically different. 
 
Table 3.1: List of murine antibodies. 
 
Antigen Fluorochrome Clone Supplier 
CD45 PerCP 30-F11 Biolegend 
CD45 V450 30-F11 BD Bioscience 
CD45 BV605 30-F11 BD Bioscience 
CD11b Pacific Blue M1/70 Biolegend 
CD11b PE M1/70 BD Bioscience 
CD11b PerCP-Cy5.5 M1/70 BD Bioscience 
Ly6G PeCy7 1A8 BD Bioscience 
Ly6G FITC 1A8 BD Bioscience 
Ly6C FITC AL-21 BD Bioscience 
Ly6C PE AL-21 BD Bioscience 
F4/80 Alexa 647 CI:A3-1 AbD Serotec 
ICAM-1/CD54 APC YN1/1.7.4 Biolegend 
CD62L PE MEL14 eBioscience 
Gr-1 APC RB6-8C5 BD Bioscience 
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Table 3.2: List of murine Taqman probes for qPCR. 
 
Gene name Code 
Ccr1 Mm01216147_m1 
Ccr2 Mm_00438270_m1 
Ccr5 Mm04207879_m1 
Cxcr4 Mm_01292123_m1 
Vegfa Mm00437306_m1 
Tnf-a Mm00443258_m1 
Alox5 Mm01182747_m1 
Arg1 Mm_00475988_m1 
Gapdh Mm99999915_g1 
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3.2 Neutrophils in High grade glioma materials and methods 
 
 Patients 
Al total of 6 patients with grade III glioma, 4 patients with IV grade glioma 
(glioblastoma) and 4 heathy controls were enrolled in the study. Patients were stratified 
based on histological classification. This study was approved by the clinical committee 
of Humanitas Clinical and Research Center. All patients signed an informed consent 
document. 
 
 Blood collection 
Blood was collected the day before the surgery in vacutainer containing 2KD-EDTA 
spray coated tubes (BD Bioscience), washed in FACS buffer (PBS-/-, 1% BSA, 0.05 
% sodium azide), red blood cells were lysed, washed again and cells were stained as 
indicated. 
 
 Tissue collection and dissociation 
Tumor core identified by PET analysis removed and washed in PBS-/-. 0.2 g of tissue 
were put in C tube (Miltenyi Biotec) and mechanical disaggregated using 
GentleMACS (Miltenyi Biotec). Later, cells were filtered in 70 µm cell strainer and 
red blood cells were lysed, washed again and cells were stained as indicated. 
 
 Flow cytometry 
Flow cytometry analysis were performed as previously described [222]. Fc receptors 
were blocked with incubation with 1% human serum (Sigma). Single cell suspension 
was stained with antibodies listed in table 3.3 and related isotype. All antibodies were 
purchased from BD Bioscience and BioLegend. Later, to exclude death cells from 
analysis, cells were stained with Violet dead cell stain kit (Biolegend). Flow cytometry 
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data were acquired using a FACS A5 Symphony (BD Bioscience) and data were 
analyzed with FlowJo Software (Tree Star).  
 
 Statistical analysis 
Data are represented as mean. In all figures sample variation is shown as SD. P value 
was generated using the unpaired t test (GraphPad Prism 5). * = p < 0.05, ** = p < 
0.01, *** = p < 0.001, ns = not statistically different. 
 
Table 3.3: List of human antibodies. 
 
Antigen Fluorochrome Clone Supplier 
L/D BV510 Zombie Biolegend 
CD45 APC-Cy7 2D1 BD 
CD14 FITC M5E2 BD 
CD15 BV710 W6D3 BD 
CD16 PE 594 3G8 Biolegend 
Syto16 FITC  Thermo Fisher 
CD66b AF700 G10F5 Biolegend 
CD3 BV570 UCHT1 Biolegend 
CD19 BV570 HIB19 Biolegend 
CD56 BV570 5.1H11(NCAM) Biolegend 
CD11b BV605 ICRF44 Biolegend 
CD54 APC HA58 Biolegend 
CD62L BV650 DREG56 Biolegend 
CCR2 BV421 48607 BD 
CXCR1 Percp-Cy5.5 8F1/CXCR1 Biolegend 
CXCR2 PE-Cy7 E8/CXCR2 Biolegend 
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4 RESULTS 
 
4.1 Study of the role of ACKR2 in the intrinsic pathway of 
cancer 
To study the role of ACKR2 in the intrinsic pathway of cancer, we use NeuT mice as 
model of Her2+ breast cancer and we evaluated tumor growth and lung metastasis 
development as sign of disease severity. 
 
 Ackr2-/- mice are protected against tumor metastasis 
In order to extend previous studies on ACKR2 in carcinogenesis, we crossed Balb/c 
WT and Ackr2-/- mice with Balb/c NeuT mice, which overexpress the rat HER2 (Neu) 
oncogene under the mouse mammary tumor virus (MMTV) promoter and 
spontaneously develop mammary carcinomas closely recapitulating human breast 
carcinogenesis [223]. We followed primary tumor development measuring time of 
appearance and volume, and we found that in NeuT/Ackr2-/- mice tumoral masses in 
mammary glands developed earlier and reached higher volumes as compared to 
NeuT/Ackr2+/+ mice (Fig. 4.1A). This result is in accordance with previous reports 
showing that ACKR2 genetic deficiency results in increased growth of primary tumors 
[69, 224]. Unexpectedly, lung analysis revealed less metastatic lesions in NeuT/Ackr2-
/- mice as compared to NeuT/Ackr2+/+ mice (Fig. 4.1B and C). 
In an effort to strengthen and extend these findings, we use also the mammary 
carcinoma tumor lines 4T1. 4T1 tumor cells were transplanted ortotopically in the 
mammary fat pad of WT and Ackr2-/- mice and no difference in primary tumor growth 
was detected (Fig. 4.1D), but again the number of spontaneous lung metastasis was 
significantly lower in Ackr2-/- mice (Fig. 4.1E and F). These findings reveal an 
opposite role of ACKR2 in tumor biology. ACKR2 deletion has a pro-tumoral role in 
primary tumor growth in NeuT model and, at the same time a protective role in lung 
metastasis development in NeuT and 4T1 models. 
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Figure 4.1: Ackr2-/- mice are protected from lung metastasis. 
A) NeuT/Ackr2+/+ (white symbols) and NeuT/Ackr2-/- (black symbols) mice were 
evaluated for tumor growth calculated as described in the Materials and Methods 
section (n = 42 and 23 for NeuT/Ackr2+/+ and NeuT/Ackr2-/- mice, respectively). B) 
Representative images of hematoxylin and eosin staining of NeuT/Ackr2+/+ and 
NeuT/Ackr2-/- lungs at 25 weeks of age. Magnification: 10X. Scale bar: 500 µm. C) 
Lung metastatic rate of NeuT/Ackr2+/+ (white column) and NeuT/Ackr2-/- (black 
column) mice, calculated as described in the Materials and Methods section (n = 26 
and 16 for NeuT/Ackr2+/+ and NeuT/Ackr2-/- mice, respectively). D) Tumor volume 
in WT (white symbols) and Ackr2-/- (black symbols) mice injected orthotopically with 
4T1 cells. (n = 14 and 13 for WT and Ackr2-/- mice, respectively). E) Representative 
images of hematoxylin and eosin staining of WT and Ackr2-/- lungs at day 28 after 4T1 
cell injection. Magnification: 10X. Scale bar: 500 µm. F) Lung metastatic rate of WT 
(white columns) and Ackr2-/- (black columns) mice at day 28 after orthotopic injection 
of 4T1 cells (n = 14 WT and 13 Ackr2-/- mice). 
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 ACKR2 in the hematopoietic compartment is responsible of the 
protection 
In order to determine the contribution of Ackr2 expressed by hematopoietic cells in 
the metastatic phenotype, we performed BM chimera experiments. We found that WT 
mice reconstitute with Ackr2-/- BM recapitulate the lung metastasis levels found in 
Ackr2-/- control (Fig. 4.2A) indicating that the protective phenotype is due to lack of 
ACKR2 by hematopoietic cells. 
The two breast cancer models used in our experiments are known to induce expansion 
and mobilization of myeloid cells, which then promote tumor growth [169, 225]. 
Interestingly, when animals were challenged with the 4T1 sibling cell line 66cl4, 
which on the opposite is unable to induce myeloid cell expansion because lack in the 
production of cytokine that influence myeloid cell recruitment such as G-CSF and 
GM-CSF [226, 227], we did not find any difference in the number of metastatic lesions 
between WT and Ackr2-/- mice (Fig. 4.2B). 
 
 
Figure 4.2: Hematopoietic expression of ACKR2 cause lung metastasis 
protection. 
A) Lung metastatic rate using 4T1 model in bone marrow chimeric mice (Donor → 
Recipient) calculated as described in the Materials and Methods section (n = 6 for WT 
and 4 for Ackr2-/- recipient mice, respectively). B) Lung metastatic rate of WT (white 
columns) and Ackr2-/- (black columns) mice at day 28 after orthotopic injection of 4T1 
or 4T1 66cl4 cells (n = 14 WT and 13 Ackr2-/- mice for 4T1, 4 WT and 4 Ackr2-/- mice 
for 4T1 66cl4).  
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 Neutrophil and monocytes are increased in blood and lung of Ackr2-/- 
mice  
We therefore focused on effects of Ackr2 genetic inactivation on the myeloid 
compartment of tumor-bearing mice as a potential mechanism of protection from 
metastasis. As previously reported, in resting conditions Ackr2-/- mice present 
increased number of inflammatory monocytes compared to WT mice while there is no 
difference in the number of other circulating leukocytes [56]. When we analyzed 
circulating and lung infiltrating leukocyte subsets in tumor-bearing mice (Gating 
strategy fig. 4.3A and B), we found, as expected, an increased circulating Ly6G+ 
neutrophils and Ly6Chigh inflammatory monocytes in NeuT/Ackr2+/+ mice (Fig. 4.4A 
and B, respectively) compared with resting WT and Ackr2-/- mice. 
When we crossed Ackr2-/- mice with NeuT mice we found that the absolute number of 
neutrophils and monocytes was further increased compared to NeuT/Ackr2+/+ mice 
(Fig. 4.4A and B, respectively). Increased number of inflammatory neutrophils and 
monocytes, but not alveolar or interstitial macrophages, was detected also in the lung 
of NeuT/Ackr2-/- as compared to NeuT/Ackr2+/+ mice (Fig. 4.4C). Lung 
immunohistochemistry also showed a higher number of Ly6G+ neutrophils in the 
parenchyma of NeuT/Ackr2-/- lungs compared with NeuT/Ackr2+/+ mice, confirming 
flow cytometry data (Fig. 4.4D and E). In 4T1 model, analysis of myeloid cells in the 
BM at day 14 after tumor injection showed a reduced number of monocytes and 
neutrophils in the BM of Ackr2-/- animals compared to WT mice (Fig. 4.4F) while no 
differences were found in vehicle-injected mice. These results indicate that, under 
tumor challenge, Ackr2-/- mice show enhanced release from BM of myeloid cells, 
which then accumulate in the blood stream and seed peripheral organs. 
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Figure 4.3: Flow cytometry gating strategy for the analysis of circulating and lung 
infiltrating neutrophil and inflammatory monocytes. 
A) Gating strategy to identification of circulating neutrophils (CD45+/CD11b+/Ly6G+) 
and inflammatory monocytes (CD45+/CD11b+/Ly6Chi). B) Gating strategy for the 
identification of interstitial macrophages (P1; CD11b+/F4/80int/Ly6C-/CD11c-/Ly6G-) 
alveolar macrophages (P2: CD11blow/F4/80hi/Ly6Cint/CD11c+/Ly6G-), inflammatory 
monocytes (P3; CD11b+/F4/80int/Ly6Chi/CD11c-/Ly6G-), and neutrophils (P4; 
CD11b+/F4/80-/Ly6Cint/CD11c-/Ly6G+) in the lungs of tumor-bearing mice. 
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Figure 4.4: Protection from metastasis in Ackr2-/- mice is associated with 
increased numbers of monocytes and neutrophils in blood and lungs. 
A) Absolute number of circulating neutrophils (CD45+/CD11b+/Ly6G+) and B) 
inflammatory monocytes (CD45+/CD11b+/Ly6Chi) in NeuT/Ackr2+/+ (white squares), 
NeuT/Ackr2-/- (black squares), WT (white triangles) and Ackr2-/- (black triangles) 
mice (n = 6 – 9 for NeuT/Ackr2+/+ mice, 5 – 7 for NeuT/Ackr2-/- mice, 3 - 5 for WT 
and Ackr2-/- mice). C) Absolute number of neutrophils, inflammatory monocytes, 
alveolar (CD11blow/F4/80+/Ly6Cint/CD11c+/Ly6G-) and interstitial macrophages 
(CD11b+/F4/80int/Ly6C-/CD11c-/Ly6G-) in the lungs of NeuT/Ackr2+/+ (white 
columns) and NeuT/Ackr2-/- (black columns) mice at 15 weeks of age (n = 12 and 6 
for NeuT/Ackr2+/+ and NeuT/Ackr2-/- mice, respectively). D) Representative 
immunohistochemical images of Ly6G staining in NeuT/Ackr2+/+ and NeuT/Ackr2-/- 
lungs at 25 weeks of age. Magnification: 20X. Scale bar: 100 µm. E) Quantification 
of Ly6G immunohistochemical images as DAB positive cells on field of view (n = 9 
and 8 for NeuT/Ackr2+/+ and NeuT/Ackr2-/- mice, respectively). F) Absolute number 
of neutrophils and inflammatory monocytes in the BM of WT (white columns) and 
Ackr2-/- (black columns) mice on day 14 after orthotopic injection of PBS or 4T1 cells 
(n = 4 for both WT and Ackr2-/- mice). 
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 Neutrophils are required for metastasis protection in Ackr2-/- mice 
To investigate the relevance of the increased myeloid cell mobilization found in Ackr2-
/- mice in the metastatic process, the B16F10 melanoma cell line was injected i.v. in a 
classic “artificial” hematogenous metastasis model.  
Also in this experimental setting, Ackr2-/- mice showed a significant reduction in the 
number of metastatic foci in the lungs as compared to WT animals (Fig. 4.5A). In order 
to understand which myeloid cells are responsible for metastasis protection, we 
performed depletion experiments using monoclonal antibodies. Macrophages 
depletion by treatment with an a-CD115 monoclonal antibody significantly decreased 
the number of metastasis in WT mice, but did not reverse the protection observed in 
Ackr2-/- mice (Fig. 4.5B). B cell depletion (performed with a-CD20 administration) 
did not modify the metastatic rate in WT and Ackr2-/- (Fig. 4.5C). Interestingly, 
neutrophil depletion with a-Ly6G monoclonal antibody caused a reduction in 
metastasis in WT mice while, on the contrary, an increase in metastasis in Ackr2-/- 
mice, which in the absence of neutrophils lost their protection and developed a number 
of metastasis comparable to WT animals (Fig. 4.5D).  
The protective role of neutrophils in Ackr2-/- mice was also demonstrated performing 
depletion experiments with the ortotopically transplanted tumor lines 4T1. Also in this 
tumor, the number of metastasis in WT mice are reduced by neutrophil depletion while 
it is increased in Ackr2-/- mice (Fig. 4.5E). 
The role of Ackr2-/- neutrophils in metastasis protection was further supported by 
adoptive transfer experiments. Transfer of Ackr2-/- but not WT neutrophils into WT 
tumor-bearing mice significantly reduced the number of metastasis (Fig. 4.5F) to 
numbers comparable to those observed in Ackr2-/- tumor-bearing mice (Fig. 4.5A). 
These results indicate Ackr2-/- neutrophils as leukocytes population with antimetastatic 
activity.  
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Figure 4.5: Ackr2-/- neutrophils are responsible of metastasis protection. 
A) Lung metastatic rate in WT and Ackr2-/- mice 10 days after i.v. injection of B16-
F10 cells. Number of metastasis was normalized on WT mice. B-D) Metastatic rate in 
WT and Ackr2-/- mice depleted for macrophages with a-CD115 (B), B cells with a-
CD20 (C) and neutrophils with a-Ly6G (D) 10 days after i.v. injection of B16-F10 
cells. Number of metastasis was normalized on WT mice treated with an irrelevant 
antibody (IgG) (n = 5 – 10 for WT mice, 5 – 8 for Ackr2-/- mice). E) Metastatic rate in 
WT and Ackr2-/- mice depleted for neutrophils with a-Ly6G 28 days after orthotopic 
injection of 4T1 cells (n = 3 for WT mice, 3 – 5 for Ackr2-/- mice). Number of 
metastasis was normalized on WT mice treated with an irrelevant antibody (IgG). F) 
Metastatic rate in WT mice 10 days after i.v. injection of B16-F10 cells and adoptive 
transfer of WT (white dots) or Ackr2-/- neutrophils (black dots) or PBS (grey dots). 
Number of metastasis was normalized on PBS injected mice. Representative images 
of excised lungs are shown on the left.  
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4.2 Analysis of neutrophil phenotype in Ackr2-/- mice 
We demonstrated that ACKR2 expression in hematopoietic compartment is 
responsible of the protection and neutrophils are the leukocytes involved in the 
protection. Our objective was to analyze neutrophils phenotype in Ackr2-/- mice to 
describe ACKR2 role on neutrophils biology.  
 
 Hematopoietic Ackr2 expression impairs in vivo neutrophil 
mobilization 
To investigate the role of ACKR2 in neutrophil infiltration in lungs, we performed 
experiments of leukocyte mobilization in BM chimeric mice. After one hour from i.p. 
injection of CCL3L1, a ACKR2, CCR1, CCR3 and CCR5 ligand known to induce 
rapid neutrophil mobilization [228], we analyzed blood and lung infiltrating 
neutrophils in bone marrow chimeric mice to assess if hematopoietic ACKR2 
expression altered neutrophils mobilization. I.p. injection causes a systemic spread of 
CCL3L1 and cause an increase of neutrophil extravasation in tissues including the 
lung. 
Results showed an increase in the number of circulating (Fig. 4.6A) and lung 
infiltrating neutrophils (Fig. 4.6B) in either WT or Ackr2-/- host animals when 
transplanted with Ackr2-/- but not whit WT hematopoietic cells, demonstrating that the 
increased neutrophil mobilization induced by CCL3L1 injection was caused by the 
absence of ACKR2 on the hematopoietic compartment. To exclude the role of other 
hematopoietic cells, we performed adoptive transfer experiment. We transfer WT and 
Ackr2-/- CD45.2 neutrophil in WT CD45.1 recipient challenged with CCL3L1. After 
one hour from the injection, we registered an increased infiltration in the lung of Ackr2-
/- CD45.2 neutrophils in WT CD45.1 mice (Fig. 4.6C) with a concomitant decrease in 
the blood (Fig. 4.6D) indicating and increase activity to extravasate from blood to lung. 
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Figure 4.6: Hematopoietic ACKR2 expression increased neutrophils mobilization 
and lung infiltration in vivo. 
A and B) Absolute number of circulating (A) and lung infiltrating (B) neutrophils in 
bone marrow chimeric mice (Donor → Recipient) after one hour from i.p. injection of 
CCL3L1 (n = 6 for WT and 4 for Ackr2-/- recipient mice, respectively). C) WT and 
Ackr2-/- CD45.2 neutrophils percentage on transferred neutrophils after one hour from 
i.p. injection of CCL3L1 (n = 3 recipient for each group). D) Absolute number of 
circulating WT and Ackr2-/- CD45.2 neutrophils after one hour from i.p. injection of 
CCL3L1 (n = 3 recipient for each group). 
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 ACKR2 impairs CC chemokines expression in neutrophils 
To elucidate the increased neutrophil mobilization in Ackr2-/- mice, we investigated 
chemokine receptor expression. Being CCL3L1 a ligand of CCR1, CCR3 and CCR5 
we investigated the role of these and other chemokine receptor in neutrophils. We 
exclude from the analysis CCR3 because it is not expressed of neutrophils [229]. We 
added analysis of CCR2 as a chemokine receptor involved in neutrophils migration 
and functional activity [149] and CXCR4 known to have an important role in 
neutrophil egression from the bone marrow [230]. RT-PCR analysis from WT and 
Ackr2-/- resting bone marrow neutrophils revealed an increase of the expression of 
CCR1, CCR2 and CCR5 (Fig. 4.7A) but not CXCR4. This result indicates that the 
increased capacity of neutrophil to migrate in vivo are associated with a selectively 
increased expression of chemokine receptors. 
 
 
 
Figure 4.7: ACKR2 impairs CC but not CXC chemokine receptor expression. 
A) qPCR analysis of chemokine receptors in FACS sorted WT (white columns) and 
Ackr2-/- (black columns) neutrophils (n = 4 for both WT and Ackr2-/- mice, two 
independent experiments). Data are relative to GAPDH expression. 
  
Cx
cr4 Cc
r1
Cc
r2
Cc
r5
0.00
0.02
0.04
1
2
3
5
15
25 **
***
***Ge
ne
 tr
an
sc
rip
t
(re
la
tiv
e 
ex
pr
es
si
on
; %
)
A 
 56 
 ACKR2-deficient neutrophils have an activated phenotype 
Neutrophil, as previously discussed, can be polarized in N1 (anti-tumoral) and N2 
(pro-tumoral) phenotype. To asses if Ackr2-/- neutrophil show features belonging to 
polarized phenotype, we performed flow cytometry analysis of circulating neutrophils. 
We analyzed surface markers know to be involved in neutrophil activation: CD62L/L-
selectin that is shed prior to neutrophil extravasation [119] and ICAM-1 that after 
binding with ICAM-1 on the endothelium allow neutrophils diapedesis [82]. 
In B16F10 model, we observed decrease of CD62L expression in Ackr2-/- mice 
compared to WT control (Fig. 4.8A and B) indicating an increased potential of 
neutrophil extravasation. At the same time, we found an increased expression of 
ICAM-1 in Ackr2-/- neutrophil (Fig. 4.8C and D) indicating the increased capacity to 
extravasate confirming an activated phenotype of Ackr2-/- neutrophils. No differences 
again were found in basal control for CD62L and ICAM-1 expression (Fig. 4.8B and 
D). We analyzed also by q-PCR a panel of gene involved in neutrophil biology 
described to be regulated in neutrophil polarization [10] and we found no difference 
in the expression of Tnf-α, Alox5, Vegfa and Arg1 (Fig. 4.8E). In 4T1 model, we 
observed a decreased level of CD62L in basal conditions between WT and Ackr2-/- 
neutrophil but not in tumor bearing mice (Fig. 4.8F). Similar data was obtained in 4T1 
model: ICAM-1 is increased in Ackr2-/- tumor bearing mice and no difference were 
found in basal control (Fig. 4.8G). These results indicate an activated phenotype of 
Ackr2-/- neutrophils that associated with antimestatic activity in B16F10 model 
previously described (Fig. 4.5F) indicate a N1 phenotype both in term of expression 
of cell surface molecules and in vivo functional activity. 
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Figure 4.8: Ackr2-/- neutrophils have activated phenotype and increased 
expression of inflammatory CC chemokine receptors. 
A) Representative histograms and B) quantifications of CD62L expression. CD62L 
mean fluorescence intensity (MFI) was normalized on WT neutrophils injected with 
PBS. C) Representative plot and D) quantification of percentage of ICAM-1 positive 
circulating neutrophils (CD45+/CD11b+/Ly6G+) in WT and Ackr2-/- mice 10 days after 
i.v. injection with B16-F10 cells. Negative gate was set on isotype control. E) qPCR 
analysis of activation markers in FACS sorted WT (white columns) and Ackr2-/- (black 
columns) neutrophils (n = 4 for both WT and Ackr2-/- mice, two independent 
experiments). Data are relative to GAPDH expression. F) Quantifications of CD62L 
expression. CD62L mean fluorescence intensity (MFI) was normalized on WT 
neutrophils injected with PBS. G) Quantification of percentage of ICAM-1 positive 
circulating neutrophils (CD45+/CD11b+/Ly6G+) in WT and Ackr2-/- mice 7 days after 
orthotopic injection with 4T1 cells. Negative gate was set on isotype control.  
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 ACKR2-deficient neutrophils increased ROS production 
To investigate functional molecule involved in neutrophil polarization, we analyzed 
reactive oxygen species (ROS) production of circulating neutrophil from tumor 
bearing mice by flow cytometry. We found an increase of ROS production in Ackr2-/- 
neutrophil in both B16F10 (Fig. 4.9A) and 4T1 model (Fig. 4.9B). Chemokine receptor 
are known to induce neutrophil ROS production [109] and our objective was to 
investigate if the increased transcript expression of CCR2 in Ackr2-/- have a functional 
role in our system. We noticed that Ackr2-/- neutrophil have an increased ROS activity 
even in basal condition (Fig. 4.9C) and after CCR2 stimulation through the ligand 
CCL2, Ackr2-/- neutrophil display an increased ROS production indicating the receptor 
have a function role in Ackr2-/- neutrophil biology (Fig. 4.9C). 
 
 
Figure 4.9: ACKR2 impair neutrophil ROS production in vivo and in vitro. 
A) MFI of cellROX in WT and Ackr2-/- neutrophils taken from mice 10 days after 
orthotopic injection of B16F10 cells. CellROX MFI was normalized on WT 
neutrophils. B) MFI of cellROX in WT and Ackr2-/- neutrophils taken from mice 7 
days after orthotopic injection of 4T1 cells. CellROX MFI was normalized on WT 
neutrophils. C) CellROX MFI in WT (white columns) and Ackr2-/- (black columns) 
neutrophils preincubated with PBS or LPS (100 ng/ml, 20 min) and stimulated with 
CCL2 (500 ng/ml, 30 min) or PMA (50 ng/ml, 30 min). CellROX MFI was normalized 
on basal WT group (n = 4, two independent experiments for both WT and Ackr2-/- 
mice). 
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 ACKR2-deficient neutrophils have increased cytotoxic activity 
The increased ROS production in Ackr2-/- mice could have a role in direct cell killing 
of cancer cell by neutrophil. We assessed in vitro cell killing in order to evaluate anti-
metastatic potential of neutrophils and we performed ROS inhibition to dissect ROS 
contribution in cell killing. WT and Ackr2-/- neutrophils separated from 4T1 tumor 
bearing mice were co-cultured with 4T1 luciferase expressing cells to determinate cell 
killing assay. We registered an increased cell killing by Ackr2-/- neutrophil compared 
to WT control (Fig. 4.10A). ROS inhibition performed with apocynin, an inhibitor of 
NADPH oxidase complex [109], inhibits cell killing in WT mice and in Ackr2-/- but 
not abrogates difference between WT and Ackr2-/- neutrophils (Fig. 4.10A). 
Similar results were obtained using neutrophils from bone marrow of resting mice. 
Ackr2-/- neutrophils display an increased tumoral killing activity (Fig. 4.10B), ROS 
inhibitor apocynin decreases cells killing in WT and Ackr2-/- neutrophils but not 
abrogates the different cell killing ability between WT and Ackr2-/- neutrophils (Fig. 
4.10B). 
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Figure 4.10: Ackr2-/- neutrophil show a ROS-dependent cell killing activity in 
vitro. 
A) In vitro cell killing activity against 4T1-luc cells of circulating neutrophils 
magnetically separated from WT and Ackr2-/- mice after 21 days from orthotopic 4T1 
injection. DMSO or Apocynin (100 µM) was added to inhibit ROS activity (n = 3, two 
independent experiments for both WT and Ackr2-/- mice). B) In vitro cell killing 
activity against 4T1-luc cells of resting bone marrow neutrophils magnetically 
separated from WT and Ackr2-/- mice. DMSO or Apocynin (100 µM) was added to 
inhibit ROS activity (n = 3, two independent experiments for both WT and Ackr2-/- 
mice). 
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4.3 Analysis of human neutrophils in glioma patients  
In the previous paragraph, we assessed an anti-tumoral role of neutrophil in ACKR2-
deficient mice. Our aim was to investigate the neutrophil phenotype in a human cancer 
context. We select high grade glioma (grade III and GBM) because are tumor types in 
which a strong systemic immunosuppressive environment is described [188]. We 
select also this type of cancer because we have the practical access to fresh blood and 
tissue samples, fundamental for neutrophils flow cytometry analysis. We analyzed 
relative neutrophil abundance on total leukocytes, their phenotype and subsets the day 
before the surgery and we correlated with TANs abundance. 
 
 Detection of circulating neutrophils and monocytes in high grade 
glioma patients 
In order to investigate human circulating neutrophil rate and phenotype we perform 
multiparametric flow cytometry analysis on total blood leukocytes. We identified 
neutrophils as CD45+/CD3-/CD19-/CD56-/CD15+/CD16+ (Fig. 4.11A). We analyzed 
by flow cytometry neutrophil rate to total leucocytes (CD45 positive cells) in healthy 
patients, glioma grade III and GBM patients. While in healthy control and grade three 
glioma patients we observed about 65% of circulating neutrophils, in GBM patients 
we found an increased neutrophil rate of 82% (SD = 6.74) (Fig. 4.11B). This result 
confirms previous data [202] that indicate neutrophilia as a feature of GBM patients 
due to increase granulocytosis and neutrophil mobilization for increased CXCL8 
[231], G-CSF [203, 204]. With the same staining, we are able to identify monocytes 
as CD45+/CD3-/CD19-/CD56-/CD15-/SSCint (Fig. 4.11A). We found no difference are 
found in term of relative monocytosis, all the groups have the same rate of circulating 
monocytes (Fig. 4.11C). Based on this evidences, we foucus our attention on 
neutrophils evaluating their subsets and activatory status. 
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Figure 4.11: GBM patients have relative neutrophilia but not monocytosys. 
A) Gating strategy to identification of circulating neutrophils (CD45+/CD3-/CD19-
/CD56-/CD15+/CD16+) and monocytes neutrophils (CD45+/CD3-/CD19-/CD56-
/CD15-/SSCint) B) Relative neutrophil rate on total leukocytes (CD45+ cells). C) 
Relative monocytes rate on total leukocytes (CD45+ cells). 
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 Circulating neutrophil subsets in GBM patients  
As previously described, granulopoiesis is altered in GBM patients. We set a flow 
cytometry approach to gate circulating and infiltrating neutrophils and their subsets. It 
is reported that neutrophils are a heterogeneous population and neutrophils subset can 
be identified in pathological situation such as sepsis and cancer evaluating expression 
of CD62L and CD16 [122]. We identified those populations also in our patients cohort 
(Fig. 4.12A) and we found in GBM patients a strong increase of immature 
CD16low/CD62L+ neutrophils that are not present in healthy controls (Fig. 4.12B). We 
observed also a concomitant reduction of “classical” neutrophils CD62L+/CD16+ rate 
in GBM compared to healthy controls (Fig. 4.12C). Finally, only a trend in the increase 
of activated neutrophils CD62Lneg/CD16+ in GBM patients was detected (Fig. 4.12D). 
These results indicate a differential presence of neutrophils subsets in GBM patients 
indicating an altered neutrophil release from bone marrow and a different maturation 
status.  
To assess neutrophils activation status in HGG patients compared to heatlhy subjects, 
we analyzed a panel of functional molecules involved in neutrophil biology. We 
noticed any difference in the expression on total neutrophil from healthy subjects and 
patients of CD11b (Fig. 4.12E), ICAM-1 (Fig. 4.12F), CXCR1 (Fig. 4.12G), CXCR2 
(Fig. 4.12H) and CCR2 (Fig. 4.12I). 
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Figure 4.12: GBM patients display altered neutrophils subsets ration. 
A) Representative dot plot of healthy control or GBM patient showing an altered 
neutrophil subsets ratio. B – D) Relative abundance on total neutrophils of (B) 
CD16low/CD62L+ cells, (C) CD62L+/CD16+, (D) CD62Lneg/CD16+. E – I) MFI or 
percentage of expression on total neutrophil of (E) CD11b, (F) ICAM-1 (G) CXCR1, 
(H) CXCR2, (I) CCR2.  
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 Increased neutrophilia is associated with increased neutrophil 
infiltration  
Neutrophils infiltrate tumor lesion in the brain [200] and to assess if increased 
neutrophilia in blood is associated with increased neutrophils infiltration rate we 
performed flow cytometry analysis on immune infiltrate in glioma lesion. We set 
protocol to dissociate and stain infiltrating neutrophils in brain lesion (Fig. 4.13A) and 
we found a positive correlation between circulating neutrophils rate and infiltrating 
neutrophils rate on total CD45+ cells (Fig. 4.13B). These results indicate that increased 
circulating neutrophils rate is reflected on infiltrating neutrophil abundance. 
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Figure 4.13: Circulating neutrophils rate is positively associated with infiltrating 
neutrophils rate. 
A) Gating strategy for the identification of infiltrating neutrophils 
(CD45+/CD15+/CD16+/CD11b+/CD66b+) B) Linear correlation between circulating 
and infiltrating neutrophils in brain lesion.  
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5 DISCUSSION 
 
Chemokines are small cytokine with chemotactic function and play a pivotal role in 
the inflammation process and in cancer [31]. Negative control of inflammation is an 
essential aspect of resolution of inflammation and its target represents a concrete 
therapeutic to limit tumor growth and metastatic spread [25]. Atypical chemokine 
receptors are a distinct family of receptors that control chemokine bioavailability. They 
scavenge, transport chemokines and represent one important mechanisms of control of 
the chemokine system [37]. ACKR2 (also known as D6) is a negative regulator of 
inflammation because it leads to degradation many inflammatory CC chemokines [40]. 
Previously studies using ACKR2 gene-targeted mice describe an important role for 
this receptor in the control of inflammation because it dampens excessive 
inflammatory responses and accumulation of leukocytes with pro-inflammatory 
phenotype [232]. Also in cancer model, Ackr2-/- mice treated with inflammatory and 
mutagen compounds that recapitulate the extrinsic pathway of tumor development, 
shown an increased tumor growth [38]. These data indicate an important role for 
ACKR2 in the control of the inflammatory process that can promote carcinogenesis. 
The aim of this thesis was to study the role of ACKR2 in the intrinsic pathway of 
cancer. We used NeuT mice, that express the rat oncogene HER2 under the mouse 
mammary tumor virus (MMTV) promoter, and develop breast cancer. Ackr2-/- mice 
crossed with NeuT mice showed an increased tumor growth compared to 
NeuT/Ackr2+/+ mice recapitulating the role of ACKR2 found in skin and colorectal 
cancer models [61, 69]. Surprisingly, despite enhanced tumor growth, NeuT/Ackr2-/- 
mice were partially protected from lung metastasis, indicating a double role of ACKR2 
in this tumor model. Lung metastasis protection in Ackr2-/- mice was also 
demonstrated in mice injected orthotopically with the breast cancer cell line 4T1 and 
in mice injected i.v. in a classic “artificial” hematogenous metastasis model with the 
melanoma cell line B16F10. 
In order to understand if ACKR2 plays a role in the hematopoietic or stromal 
compartment, we performed bone marrow chimera experiment in the 4T1 model and 
we recapitulate the protection of Ackr2-/- mice transferring Ackr2-/- bone marrow in 
WT host. These results indicate that ACKR2 expression in the hematopoietic 
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compartment is responsible of the protection. We associated also metastasis protection 
to increased number of circulating neutrophils and monocytes in NeuT/Ackr2-/- mice. 
To assess which leukocyte population was involved in the metastasis protection, we 
performed cell depletion using monoclonal antibody. Only when neutrophils were 
depleted, but not monocytes or B cells, Ackr2-/- mice increased metastatic rate 
compared to WT levels in B16F10 and 4T1 model. We prove also that neutrophil-
mediated protection in Ackr2-/- mice was due to neutrophils performing adoptive 
transfer experiments. Only the transfer of Ackr2-/- neutrophils in B16F10 WT bearing 
mice recapitulated the phenotype of Ackr2-/- mice. Following these results, we focused 
our attention to Ackr2-/- neutrophils in order to understand which was the mechanism 
of protection. We analyzed circulating neutrophil phenotype in tumor-bearing mice 
with flow cytometry techniques. Ackr2-/- neutrophils, compared to WT neutrophils, 
had increased ICAM-1 expression and lower levels of CD62L, indicating N1 
polarization or an activate state of neutrophils. Moreover, we demonstrated that Ackr2-
/- neutrophils, in a model of in vivo mobilization with the administration with CCL3L1 
chemokine, have a cell intrinsic increased mobilization from bone marrow to blood 
and are more able to infiltrate lungs. Increased cell-autonomous mobilization of 
neutrophils in Ackr2-/- mice was previously observed also in skin in a psoriasis model 
[65]. To further demonstrate the cell intrinsic increased mobilization, we performed 
the same experiment transferring CD45.2 WT and Ackr2-/- neutrophils into CD45.1 
WT mice. We found, again, an increase rate of Ackr2-/- neutrophils in the lung of WT 
mice compared to controls and a concomitant decrease of Ackr2-/- neutrophils in the 
blood due to the increased extravasation activity. These results were correlated to 
increased transcript level of chemokine receptor CCR1, CCR2 and CCR5 in Ackr2-/- 
neutrophils in resting condition that indicate a direct role of ACKR2 in the regulation 
not only of chemokines bioavailability, but also of the receptors that share the ligands 
with ACKR2. Ackr2-/- neutrophils have also an increased ROS production compared 
to WT controls in both B16F10 and 4T1 model. We demonstrated also that ROS 
production is CCR2-dependent and Ackr2-/- neutrophils have increased CCR2-
dependent ROS production compared to WT. Finally, we prove that Ackr2-/- 
neutrophils have increased direct cancer cell activity performing co-culture of WT and 
Ackr2-/- neutrophils with 4T1 luciferase-expressing cells and we found an increased 
cell killing rate of Ackr2-/- neutrophils compared to WT controls. ROS inhibition 
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abrogates cell killing by WT neutrophils and cause a cell killing decrease in Ackr2-/- 
neutrophils but not abrogates the difference between WT and Ackr2-/- neutrophils. 
These results indicated a not complete ROS-dependent mechanism of cell killing by 
Ackr2-/- neutrophils. Extensive experiments are needed to elucidate the cell killing 
mechanism in Ackr2-/- neutrophils. All these achievements indicate ACKR2 as a 
negative regulator of the mobilization of neutrophils with anti-metastatic activity 
[233]. 
Neutrophils were considered for many years as neutral players in cancer, but in the last 
decade neutrophils were emerged as a leukocyte population with different roles in 
carcinogenesis, primary tumor growth and metastatic spread [84]. Cytokines released 
in the tumor microenvironment and at systemic level modulate neutrophil maturation, 
mobilization from bone marrow and polarization [10]. These observations indicate that 
neutrophils are potential target of antitumor therapy for their direct activity against 
cancer cells [109] and for their indirect role such as regulator of angiogenesis [212]. 
Our findings reveal that ACKR2 genetic ablation in neutrophils resulted in an activated 
phenotype that inhibit tumor metastasis [233]. 
In order to understand if human neutrophils are present in different activation states in 
the blood of tumor patients, we performed flow cytometry analysis. We started to 
phenotype neutrophils in high grade glioma patients. High grade gliomas are brain 
tumors that include glioblastoma. They have a mean survival time of fifteen months 
after diagnosis. In high grade glioma patients, a severe immunosuppression is 
described with a concomitant neutrophilia in blood and presence of TANs in the brain 
lesion [188]. Increased neutrophil to lymphocytes ratio is associated with a worse 
pathology outcome while few data describe neutrophils phenotype [188, 205, 207-
209]. All these features make high grade gliomas an interesting context for the study 
of neutrophils phenotype. Our preliminary data confirm a strong neutrophilia before 
the surgery in GBM patients compared to grade III patients and heathy controls [202]. 
On the contrary, no differences were observed for monocytes. In healthy condition, 
neutrophils are described as a homogeneous population but during pathology, such as 
sepsis and cancer, neutrophil subsets with differential activation and maturation were 
described [122]. We demonstrated that also in GBM patients three distinct neutrophil 
subsets were detected based on the differential expression of CD16 and CD62L. this 
indicated that in glioma patients neutrophil maturation and activation is affected, but 
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at the moment we have not detected differences in the expression of a panel of markers 
involved in neutrophil biology. Nevertheless, we found a positive correlation between 
circulating and tumor infiltrating neutrophil abundance on total leukocytes indicating 
that increased neutrophilia is associated to enhance neutrophils activation. Further 
analyses will be necessary to better describe neutrophil phenotype and to associate 
abundance of circulating and infiltrating neutrophils and their phenotype with survival 
rate and therapy effectiveness. 
Collectively taken, our findings reveal that canonical and atypical chemokine receptor 
have an active role in the maturation and the activation of neutrophils with anti-
metastatic activity. Neutrophils and their chemokine receptors are so indicated as 
functional target during cancer pathologies in order to block pro-tumoral role and 
unleash their anti-tumoral and anti-metastatic potential.  
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